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Nicotinic acetylcholine receptors (nAChRs) are common ligand-activated neurotransmitter 
receptors located throughout the body. The up-regulation of nAChRs subunits has been observed in 
a number of cancer types; while current literature has identified various nAChR pathways that 
contribute to the development of cancer. The present study identified a novel mechanism for the 
observed cytotoxicity of the highly potent nAChR antagonist, pinnatoxin (PnTX), on human 
epithelial carcinoma cell lines. Cell cycle and intracellular calcium studies suggest that PnTX exerts 
its cytotoxic effects by inducing changes in the cell cycle via antagonism of the highly calcium 
permeable α7-, and to a certain extent, the α4β2-nAChR receptors. This leads to an induction of cell 
apoptosis via calcium-independent pathways. The use of nAChRs in combination with other known 
cytotoxic agents, such as cyclosporin A, or apoptotic inducing chemotherapy agents, may provide a 
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1.1 Nicotinic Acetylcholine Receptors 
Nicotinic acetylcholine receptors (nAChRs) are common ligand-activated neurotransmitter 
receptors located throughout the body. nAChRs respond to the binding of the endogenous 
neurotransmitter, acetylcholine (ACh), causing fast ionotropic cationic transmission through the cell 
membrane (Albuquerque et al., 2009). The receptors are expressed on both neuronal and non-
neuronal cells, resulting in a diverse range of functions. Consequently, the receptors are linked to 
many human disease states, making them one of the most intensely researched areas of molecular 
biology and therapeutics.  
1.1.1 Structure, Diversity and Localisation 
The acetylcholine receptor family is comprised of two major sub-groups of receptors; 
nAChRs and muscarinic acetylcholine receptors (mAChRs). Unlike mAChRs that relay 
intracellular messages though G-protein-coupled transmission, nAChRs gate the flow of various 
ions through the cell membrane to induce a cellular response (Albuquerque et al., 2009). The ability 
of nAChRs to regulate ion transmission stems from their pentagonal structure of five subunits, 
arranged around a central pore. Each subtype spans the length of the cell membrane, with both the 
N- and C-terminal of the subtype protein located extracellularly. The nAChR is comprised of an 
arrangement of different α, β, γ, δ and ε subtypes that dictate the flow of ions through the receptor 
pore (Kalamida et al., 2007).  
As with all members of the acetylcholine receptor family, receptor function is regulated by the 
interaction between ACh and the ligand-binding site. Binding of ACh to the receptor occurs at the 
interface between two subunits, with at least one subunit residing from the α-subunit family, on the 
extracellular domain of the receptor, as represented in Figure 1. ACh binding causes a 
conformational shift in the pentagonal structure of the receptor as a result of changes to the van der 
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Waal interactions between the receptor subunits. Opening of the transmembrane pore allows the 
movement of positively charged ions, including sodium and calcium (Ca2+) into the cell, and 
potassium out of the cell, to elicit the cellular response (Miyazawa et al., 2003). 
 
Figure 1: Protein ribbon structure of a nicotinic acetylcholine receptor, as viewed from the synaptic cleft (left) and 
parallel with the cell membrane (right). The diagram displays the pentagonal structure of a common heteromeric 
(α)2βγδ-nAChR, configured around a central pore with sections of each subunit located within the intracellular (I) and 
extracellular (E) space. The αTrp149 ligand binding region of the α-subunit has been displayed in yellow. Images 
adopted from (Unwin, 2005). 
 
The localisation of the receptor also plays a role in the expression of specific nAChR 
subunits. The sub-group of nAChRs is broadly split into two types, muscle-type and neuronal-type 
nAChRs. Muscle-type nAChRs are located at the neuromuscular junction of muscle terminals, 
where they play an important role in muscle contraction. Muscle-type nAChRs are comprised 
strictly of a (α1)2β1εδ receptor configuration in the adult muscle (embryonic muscle contains the γ-
subunit in place of the ε-subunit, with the transition of γ- to ε-subunit expression occurring during 
development) (Tzartos et al., 1998). Neuronal-type nAChRs demonstrate a higher degree of 
diversity in terms of subunit expression. Receptor pentamers can be comprised of homomeric 
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configurations of α-subunits (e.g. (α7)5), or heteromeric configurations consisting of both α- and β-
subunits (e.g. (α4)2(β2)3). As a result, the function, ionic permeability and responsiveness to various 
exogenous compounds of the neuronal-type nAChRs can differ greatly between receptor 
configurations (Sargent, 1993).  
Traditionally, the expression of nAChRs consisting of homo- and heteromeric configurations 
of α- and β-subunits was thought to be localised to within the nervous system. However, recent 
research has identified the expression of non-neuronal nAChRs on various cells outside of the 
nervous system. Various nicotinic α- and β-subunits are expressed on non-neuronal tissues, 
including endothelial cells, epithelial cells, mesenchymal cells and a variety of immune cells 
(reviewed in (Arias et al., 2009). The function of the different neuronal and non-neuronal nAChRs 
is discussed in more detail in the following sections. 
1.1.2 Neuronal nAChR Function 
Neuronal nAChRs are widely spread throughout the nervous system, including certain areas 
of the brain and within the peripheral ganglia. The nAChRs are comprised of combinations of nine 
α (α2-α10) and three β (β2-β4) subunits, forming operational ion channels at the pre-terminal, pre-
synaptic and post-synaptic sites of neuronal cells (Dajas-Bailador et al., 2004). Pre-synaptically, 
nAChRs influence neurotransmitter release through membrane depolarisation, or by altering 
intracellular Ca2+ concentration due to the high permeability of some nAChR subunit configurations 
to Ca2+. Post-synaptically, nAChRs contribute to the fast excitatory transmission of signals within 
the central nervous system (CNS), enhancing post-synaptic excitation. However, the post-synaptic 
effects of neuronal nAChRs are thought to be less relevant to their overall function in the CNS 
(Kalamida et al., 2007). 
Based on the expression of particular subunits on the pre-synaptic terminal, nAChRs in the 
CNS can regulate the release of particular neurotransmitters. For example, dopamine release has 
been found to be regulated by the expression of α4β2 and α6β2 subtypes in the mesolimbic pathway 
of the CNS (Gotti et al., 2010); while, α7 subtype expression is linked to glutamatergic 
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neurotransmission in various regions of the brain (Cui et al., 2013). The ability of nAChRs to 
regulate neurotransmission is due to their ability to cause an increase in intracellular Ca2+ levels at 
the pre-synaptic terminal. Non-α7 subtype receptor configurations, such as the α4β2, have relatively 
low permeability to Ca2+ when activated. However, these receptors are functionally coupled to 
voltage-gated calcium channels, resulting in an influx of Ca2+ into the pre-synaptic terminal 
following ACh binding (Garduño et al., 2012). Alternatively, nAChRs, such as the homomeric α7 
receptor, can induce glutamine release without the involvement of coupled ion channels, due to its 
high permeability to Ca2+ through the central pore of the receptor once activated (Garduño et al., 
2012).  
The ability of nAChR to regulate intracellular Ca2+ levels within the nervous system plays 
another important role in the regulation of neuronal gene expression. The influx of Ca2+ into the cell 
following nAChR activation of Ca2+ permeable subunits results in the downstream activation of 
transcription factors (Nakayama et al., 2006). One example is the established role of nAChRs in 
memory and plasticity events. The activation of nAChRs, especially those containing the highly 
Ca2+ permeable α7 subunits, regulates the ERK/MAPK intracellular signalling cascade. The 
prolonged activation of this signalling cascade results in the phosphorylation of various gene 
transcription factors, such as the cAMP response element binding protein (CREB), Sp1 and c-myc. 
The increase in gene transcription results in the expression of several proteins involved in memory 
formation and long-term plasticity within the nervous system (Nishimoto et al., 2011). Furthermore, 
the activation of nAChRs via exogenous agonists such as nicotine plays an important role in 
addiction through the activation of similar intracellular signalling cascades (Changeux, 2010). 
Finally, neuronal nAChR activation has been shown to be linked to neuroprotection within the 
CNS, while contributing to protection against neuronal toxicity.  nAChRs containing the α7 subtype 
have been linked to the intracellular activation of the phosphatidylinositol 3-kinase (PI3K) cascade. 
The neuronal activation of the PI3K pathway results in downstream phosphorylation of Akt, and 
subsequently Bcl-2 and Bcl-xl proteins, a subset of anti-apoptotic proteins that can prevent cell 
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death during neuronal toxicity (Kawamata et al., 2012). The interaction of neuronal nAChRs 
interaction with N-methyl-D-aspartate (NMDA) glutamate receptors has also been shown to protect 
against Ca2+ induced neurotoxicity. NMDA receptor stimulation induces an influx in Ca2+ during 
ischaemic brain injury, resulting in the over-activation of intracellular nitric oxide synthase and 
subsequent glutamate-related cell death (Akaike et al., 1994). However, activation of nAChRs 
during glutamate-induced neurotoxicity has demonstrated potential neuroprotective effects of the 
nAChRs. Pre-treatment with nicotine, a potent nAChR agonist, prior to glutamate exposure 
significantly increased cell viability in cultures of rat cortical neurons, compared to glutamate 
exposure alone (Kaneko et al., 1997). The neuroprotective effects were shown to be related to the 
inhibition of NOS through the activation of α4β2 and α7 nAChRs (Takada et al., 2003).  
1.1.3 Non-Neuronal nAChR Function 
ACh is synthesised by a large range of non-neuronal cells, with functions that differ greatly 
from the neuronal neurotransmitter role of the cholinergic system. The role of ACh in non-neuronal 
cells plays an intermediate role between the cells and the surrounding environment, facilitating cell 
proliferation, differentiation and migration, amongst other physiological processes. Blockage of 
these receptors leads to cellular dysfunction and death, highlighting their importance in normal 
cellular processes of non-neuronal cells (Wessler et al., 2008). The expression of specific nAChR 
subtypes on non-neuronal cells varies according to the cell phenotype and the intra- and 
intercellular environment. Analogous to the presence of nAChRs in the nervous system, both 
homomeric and heteromeric combinations of α- and β-nAChR subunits are expressed amongst non-
neuronal cells (Arias et al., 2009). 
 The major function of nAChRs in non-neuronal cells is the regulation of intercellular signal 
transduction through auto- and paracrine secretions of ACh (Chen et al., 2002). One example of 
non-neuronal nAChR signal transduction is the role of these receptors in epidermal cells, where the 
concentration of ACh is found at levels significantly higher than in other non-neuronal regions of 
the body (Grando et al., 2006). Real-time polymerase chain reaction and immunostaining analysis 
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of keratinocytes within the epidermis has eluded to the presence of α3, α5, α7, α9, α10, β2 and β4 
subunits; in addition to the expression of the functional enzymes required for the synthesis and 
breakdown of ACh (Kurzen et al., 2004; Nguyen et al., 2000). Autocrine and paracrine secretions 
of ACh activate keratinocyte α7-nAChRs, utilising the influx of Ca2+ into the cell as a second 
messenger. The downstream effect of the intracellular influx of Ca2+ results in the regulation of 
cellular differentiation, such as cytoskeleton reorganisation and expression of migratory integrins. 
Interestingly, the removal of the α7 signalling pathway in keratinocytes not only prevented 
differentiation of these cells, but also decreased the expression of pro-apoptotic signalling 
molecules, suggesting a secondary role of nAChR activation in keratinocyte apoptosis (Arredondo 
et al., 2002).  
Much like the role of nAChRs in epidermal signalling transduction, non-neuronal nAChRs 
are critical in the formulation of new blood vessels. Non-neuronal nAChRs have been shown to 
contribute to angiogenesis through the expression of homomeric α7 nAChRs and several 
heteromeric nAChRs, including α3, α5, β2 and β4 subunits, on endothelial cells (Arias et al., 2009). 
Stimulation of nAChRs of endothelial cells with the non-selective nAChR agonist, nicotine, induces 
endothelial tube formation in vitro (Heeschen et al., 2002). Investigation into the activation of 
endothelial cell nAChRs established that α7 homomeric receptors were the primary receptor 
involved following activation with a α7-selective agonist, dimethoxybenzylidene (Li et al., 2006); 
while tube formation was significantly reduced in the presence of the α7-selective antagonist, 
methyllycaconitine (Beckel et al., 2006). Furthermore, the non-selective blockade of nAChRs with 
α-bungarotoxin (α-BTX) reduces endothelial cell migration by significantly inhibiting fibroblast 
growth factor (FGF) and vascular endothelial growth factor (VEGF), important factors for 
regulating the adhesion between endothelial cells (Ng et al., 2007).  
Research has also shown the ability of ACh to modify the immune response through the 
expression of non-neuronal nAChRs on various immune cells via similar auto- and paracrine 
functions. The presence of ACh during in vitro immune models has demonstrated the role of ACh 
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in the induction of CD4+ T-cell maturation and in the differentiation of CD8+ T-cells into cytolytic 
T-cells (Basso et al., 2008; Zimring et al., 2005). Similarly, several nAChR subtypes have been 
identified on B lymphocytes, with both α4α5β2 and α7α5β4 receptor configurations identified. 
Murine knockouts of the α4, α7 or β2 subtypes showed that the nAChR subtypes are critically 
involved in supporting B lymphocyte survival and cellular growth (Skok et al., 2007). Conversely, 
knockdown of the α7 subunit in a murine model has been shown to increase the expression of IgG1 
antibodies in response to an antigen, compared to wild-type mice, suggesting a possible immune 
suppression role of nAChRs (Kawashima et al., 2007).   
1.1.4 nAChRs in Disease 
Due to the vast array of neuronal and non-neuronal processes that are governed by nAChRs, a 
number of pathological conditions can arise when substantial alterations of the neuronal and non-
neuronal cholinergic system occur. Neuronal nAChR’s are involved in the fine control of complex 
behaviours within the CNS, consequently, alterations to their function can contribute to the 
development of several behavioural diseases (Gotti et al., 2006). In contrast, the role of the 
cholinergic system of non-neuronal cells in disease is not well known.  
Alzheimer’s disease, the most common cause of dementia, is characterised by a distinct loss 
of cholinergic function within parts of the CNS. Recent research has alluded to the reduced numbers 
of nAChRs in Alzheimer’s patients, with the α7 subunit being of greatest importance. Treatment 
with nAChR agonists was shown to protect and delay the loss of neurons (Parri et al., 2011). 
Similarly, changes in neuronal nAChR function have been associated with schizophrenia disease. 
Studies investigating the post-mortem brains of schizophrenia patients have observed a decrease in 
cholinergic receptor expression involving the α7 and α4β2 subunits in the hippocampal and striatal 
regions of the brain (Durany et al., 2000; Freedman et al., 2000). Changes in α7 and α4β2 subunit 
expression within the CNS have also been associated with Parkinson’s disease (Meyer et al., 2009), 
autism (Martin-Ruiz et al., 2004) and attention-deficit hyperactivity disorder (Wilens et al., 2007), 
with potential selective agonists offering potential treatment benefits in these disease states. 
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 Alterations in the non-neuronal cholinergic system, such as small changes in the expression 
pattern of selected subtypes, result in similar cellular stress outside of the nervous system (Wessler 
et al., 2008). Studies have indicated a possible role of nAChRs in dermatitis, with an increase in 
acetylcholine of 14-fold in superficial and 3-fold in the underlying portion of patients with atopic 
dermatitis. In the same patients, a significant increase in choline-acetyltransferase, the enzyme 
responsible for the production of ACh, was seen in the various skin and immune cells surrounding 
the affected site (Wessler et al., 2003). In contrast, ACh content is substantially reduced in the 
blood cells and bronchi of cystic fibrosis patients (Wessler et al., 2007). The cholinergic 
dysfunction is thought to contribute to the characteristic alteration in water and ion balance during 
cystic fibrosis; while agonists of the α7-nAChR have been shown to produce anti-inflammatory 
effects in the epithelium of patients with cystic fibrosis (Greene et al., 2010). Finally, the 
overexpression of nAChR on cancer cells stimulates tumour growth when activated in various 
cancer types, with the role of nAChR in cancer development discussed in more detail in the 
following section (Paleari et al., 2008).  
 
1.2 nAChRs in Cancer Development 
Cancer is defined as the uncontrolled growth of abnormal cells within the body. The process 
by which healthy cells develop into malignant cancerous cells is complex, with a number of 
endogenous and exogenous factors contributing to cancer development. However, recent research 
has identified a range of common hallmarks acquired by cells during carcinogenesis, which allow 
the abnormal cells to proliferate and spread throughout the body. In the most simplistic form, these 
hallmarks include the ability of the cancer to sustain proliferation signalling, evade growth 
suppressors, resist cell death, enable replicative immortality, induce angiogenesis, and activate 
invasion and metastasis (Hanahan et al., 2011). The following section details the role of neuronal 
and non-neuronal nAChRs in cancer development through facilitating some of these key functional 




Figure 2: The regulation of intracellular pathways and pro-carcinogenic effects following nAChR activation. 
Endogenous and exogenous ligands bind to the specific nAChRs, causing an influx of Ca2+and other cations through 
the nAChRs and voltage-gated Ca2+channels. The large Ca2+influx triggers the activation of various second 
messengers, resulting in angiogenesis, cell proliferation and the inhibition of apoptosis. Figure adopted from (Schuller, 
2009). 
1.2.1 nAChR Expression in Cancer 
Similarly to the expression of nAChRs on normal healthy cells, multiple nAChR subtypes are 
expressed on both neuronal and non-neuronal cancer cells. The expression pattern of these subtypes 
may vary greatly between normal and cancerous cells, where variations in nAChR expression levels 
facilitate cancer development and proliferation. Extensive research has been conducted on the 
nAChR patterns of various lung cancer types, due to the link of nicotine exposure and lung cancer 
development of smokers (Egleton et al., 2008). Comparison of the expression patterns of nAChR 
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subtypes between normal and cancerous lung cell types have revealed a significant upregulation of 
the β4 subunit in non-small cell lung carcinoma (NSCLC) cells. Conversely, a decrease in α4 levels 
was shown across the same comparison (Lam et al., 2007). Interestingly, an increase in the 
expression of nAChRs has also been observed in lung cancer cells of non-smokers. A comparison 
between NSCLCs in smokers and non-smokers showed variations in the expression patterns of 
some nAChR subunits, with a higher expression of α6β3 receptors on NSCLCs of non-smokers, 
compared to those from smokers (Lam et al., 2007). One hypothesis is that other exogenous 
compounds act on nAChRs in a similar fashion to nicotine. N-nitrosodiethylamine (DeN), a 
compound commonly found in food, contains a similar structure to ACh, with a high affinity for 
both homo- and heteromeric nAChRs (Schuller, 2007). Compounds such as DeN may lead to the 
non-tobacco-regulated modulations of nAChRs and development of lung cancer in non-smokers 
(Niu et al., 2014). 
The up-regulation of nAChRs subunits has also been observed in a number of cancer types, 
with the majority of research focused on the α7 and α4β2 subtypes due to their abundance across all 
cell types (Le Novere et al., 1995). Significant levels of either receptor subtype have been identified 
on human mesothelioma (Trombino et al., 2004), colon (Wong et al., 2007), lung (Lam et al., 
2007), oesophageal (Arredondo et al., 2007), breast and pancreatic cells (Dasgupta et al., 2009). 
Nicotine affinity studies have shown the ability of nicotine to bind with a higher affinity to α4β2 
receptors, than to α7 nAChRs. The higher affinity of nicotine to α4β2 receptors causes a long-term 
desensitisation of the receptor following chronic exposure, while having no effect on the sensitivity 
of the α7 subtype (Kawai et al., 2001). Consequently, the biological function of the α7 nAChRs are 
increased following nicotine exposure, resulting in an increase in cancer cell proliferation due to the 
pro-carcinogenic effects of α7 nAChRs. Alternatively, the α4β2 receptor is mainly involved in 
inhibitory cellular functions, with desensitisation of the receptor contributing to an environment 
ideal for cancer development and proliferation (Schuller, 2009).  
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Interest surrounding the overexpression of another nAChR subtype, the α9-subunit, has grown 
recently with the subunit being linked to the development of breast cancer. Microdissected breast 
tumours of 50 human breast cancer samples have shown an average 7.84-fold increase in α9-
nAChR mRNA expression in 67.3% of the samples tested. In vivo studies inducing overexpression 
of the α9-nAChR of MCF-10A cell xenografts in nude mice have revealed a substantial increase in 
tumour growth following treatment with nicotine (mean 84% increase in tumour size) (Lee et al., 
2010). The up-regulation of the α9-nAChR expression in breast cancer has been linked to the 
activation of the estrogen receptor (ER). Prolonged exposure to estrogen and nicotine are known 
risk factors for the formation of breast cancer (Daniell, 1980). Recent studies have shown the ability 
of nicotine to act in a similar fashion to estrogen, binding to the ER and inducing gene transcription. 
The activated ER, following nicotine or estrogen exposure, can specifically bind the activating 
protein 1 (API)-binding site of the α9-nAChR gene, inducing transcription and overexpression of 
the α9-nAChR. The results indicate that the ER-induced α9-nAChR overexpression may play a 
central role in the association between nicotine or hormonal exposure and human breast cancer 
formation (Lee et al., 2011). 
 The expression of nAChRs in cancers of the CNS is less characterised than the expression 
on non-neuronal cancer types. The expression of nAChRs on normal healthy neuronal cells is well 
known, with multiple subtypes expressed, playing an important part in many physiological 
processes (see Neuronal nAChR Function) (Kalamida et al., 2007). One common form of CNS 
cancer is glioblastoma multiforme, an aggressive type of malignant glial cancer originating from 
healthy glial cells that comprise the supportive tissue within the brain (Parsons et al., 2008). 
Isolation of various glioblastoma cell types, including U87, LN18 and U373 cells, have allowed for 
effective in vitro studies into the characteristics of this aggressive tumour. However, due to the 
difficulty of delivering anti-cancer drugs through the blood brain barrier and the widespread role of 
nAChRs in many other normal CNS functions and pathological diseases, only limited investigations 
into the role of nAChRs in the development of glioblastoma have been conducted. A study 
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undertaken by (Zhan et al., 2011), has exploited the expression of nAChRs on U87 cells to facilitate 
the delivery of the chemotherapy agent paclitaxel to glioblastoma cells. Poly(ethylene glycol)-
poly(D,L-lactide) (PEG-PLA) micelles encapsulating paclitaxel were coupled with candoxin 
(CDX), a selective α7-nAChR antagonist, and injected intravenously into nude mice bearing 
intracranial U87 glioblastoma. The paclitaxel-encapsulated PEG-PLA micelles significantly 
prolonged average survival time by 7 days when coupled with CDX, compared to PEG-PLA-
Paclitaxel treatment alone. The study demonstrated the possible mechanism for exploiting 
differential expression of nAChRs on the surface of glioblastoma cancer cells (Zhan et al., 2011). 
1.2.2 nAChRs in Cancer Development and Proliferation 
One of the most fundamental characteristics of cancer cells to develop and grow is their 
ability to sustain rapid proliferation. Normal tissue cells regulate the production and release of 
various growth factors that ensure controlled progression through the cell cycle, limiting tissue 
growth. However, cancer cells lose the ability to regulate these growth factors, resulting in 
sustained and uncontrolled proliferative signalling (Hanahan et al., 2011). nAChRs have been 
shown to aid in the proliferation of cancer cells through changes in receptor expression and 
downstream signalling pathways of various receptor subtypes that contribute to the loss of 
homeostatic regulation of cell growth.  
Investigation into the proliferative signalling of nAChRs in cancer cells using potent nAChR 
agonists, such as nicotine-derived nitrosamines, has revealed several pathways important for tumour 
growth. Selective binding of nitrosamines to α7-nAChRs of pulmonary neuroendocrine cells and 
small cell lung carcinoma (SCLC) cells activates multiple intracellular signalling messengers, 
including protein kinase C (PKC), Raf1, the mitogen-activated kinases ERK1 and ERK2, and 
several transcription factors (FOS, JUN and MYC) (Jull et al., 2001). The transcription factors 
FOS, JUN and MYC induce transcription of specific promoter elements located on proliferative 
genes, such as c-erbB-1 (Volm et al., 1998). The proliferative effects following nAChR activation 
were significantly reduced through the use of a selective α7-nAChR inhibitor, Ca2+ channel 
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blockers or pharmacological inhibition of the ERK1 and ERK2 kinases, further validating the 
central role of nAChRs in cancer cell proliferation (Sheppard et al., 2000; Xu et al., 2004).  
Similar proliferative pathways related to nAChR-activation have been identified in other 
cancer models. Studies using NSCLC and other lung epithelial carcinomas have shown the 
nitrosamine-induced activation of the PI3K-Akt pathway, resulting in the phosphorylation of the 
proliferation specific p70S6-kinase messenger. The effects on cancer cell proliferation were 
comparable between selective agonists of nAChRs containing α3, α4 or α7 subunits (West et al., 
2003). Furthermore, the activation of nAChRs in breast cancer cell lines, MCF10A and MCF7 cells, 
enhances the activity of PKC-α and cell division control protein 42 (cdc42) involved in cellular 
proliferation and migration (Guo et al., 2008). While studies have suggested that the nAChR-
proliferative effects on breast cancer cells are dependent on the expression of the α9 subunit (Chen 
et al., 2011). Interestingly, the desensitisation of α4β2 receptors during prolonged exposure to 
nicotine or estrogen, as previously discussed, contributes to the proliferative state of a cancer cell. 
Studies have shown the ability of the α4β2-nAChR to regulate the release of gamma-aminobutyric 
acid (GABA), an important neurotransmitter with tumour suppressing functions. A reduction in 
GABA release has been demonstrated in nitrosamine-stimulated pulmonary adenocarcinoma cells, 
suggesting a link between α4β2 desensitising and reduced GABA expression (Schuller et al., 2008). 
Furthermore, reduced GABA levels have been observed in the brains of smokers (Epperson et al., 
2005); while a reduction in the RNA levels of the α4 subunit gene have been shown in pulmonary 
adenocarcinoma cells (Lam et al., 2007). 
nAChR signalling can influence cancer cell proliferation through synergistic functions with 
various growth factors. Stimulation of nAChRs of bovine adrenal pheochromatocytes induces the 
production and release of FGF-2, a mitogenic neurotrophic protein that controls the development 
and plasticity of various neuronal cell types. Induction of the FGF-2 growth hormone is controlled 
through the cAMP/PKC signalling pathway, a common cascade linked to nAChRs and cancer cell 
growth; while selective inhibition of the α7-nAChRs significantly reduces FGF-2 expression 
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(Brown et al., 2012; Moffett et al., 1998).  The activation of nAChRs by nicotine has also been 
shown to increase the expression of epidermal growth factor receptor (EGFR), which when 
activated by extracellular growth factors, signals cancer cell proliferation. Nicotine treatment of 
MDA-MB-231 breast cancer cells was shown to stimulate EGFR expression, via the ERK1/2 
signalling pathway, and promote breast cancer growth (Nishioka et al., 2011).  Likewise, nicotine 
induced glioma cell growth and colony formation in U87 and GBM12 cell lines through the 
increased phosphorylation of EGFR, AKT and ERK. The proliferative effects were reduced 
following the inhibition of the EGFR, PI3K and MEK pathways, suggesting the importance of 
nAChRs in cancer cell sensitisation to extracellular growth signals (Khalil et al., 2013). 
1.2.3 Role of nAChRs in Cancer Angiogenesis and Metastasis 
Analogous to normal tissues, tumours require constant access to nutrients and oxygen in order 
to proliferate. The physiological process of angiogenesis in which new vasculature is formed 
provides the required circulation for a tumour to grow. During controlled processes, such as wound 
healing, the angiogenic response is transiently activated; however, during tumour progression, the 
process of angiogenesis is poorly regulated. A phenomenon called the ‘angiogenic switch’ occurs 
where prolonged and sustained signalling for the development of new vasculature within the tumour 
microenvironment results in continuous vessel formation (Hanahan et al., 1996; Hanahan et al., 
2011). Similar to the regulation of apoptosis, angiogenesis is thought to be regulated by the 
counterbalance of pro- and anti-angiogenic factors. Several angiogenic inducers have been 
identified in the process of both healthy and tumour-associated angiogenesis. VEGF, a key player in 
the initiation of new blood vessel formation, is up-regulated in response to hypoxia and oncogene 
signalling. In addition, the pro-angiogenic factor, FGF, has been linked to sustaining tumour 
angiogenesis during prolonged expression (Baeriswyl et al., 2009; Ferrara, 2009; Hanahan et al., 
2011).  
The role of nAChRs in both normal physiological angiogenesis and tumour-associated 
angiogenesis is well established. Studies inducing nAChR activation through nicotine 
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administration in both the Lewis lung cancer model and colon cancer xenografts in mice have 
demonstrated an increase in tumour vascularity, resulting in accelerated tumour growth (Heeschen 
et al., 2001; Natori et al., 2003). Mecamylamine has been shown to partially inhibit the nicotine 
induced angiogenic response and return capillary density to control levels, suggesting the 
importance of the α7-subunit (Zhu et al., 2003). The pro-angiogenic effects mediated by the α7-
nAChR are linked to the induction of VEGF, involving various nAChR-linked signalling pathways. 
nAChR activation significantly increases VEGF expression by >2-fold in NSCLC cells (A549 and 
H157) in the presence of nicotine. The pharmacological blocking of various nAChR-mediated 
signalling pathways, including Ca2+/calmodulin, c-Src, PKC, PI3K/Akt, MAPK/ERK and mTOR, 
significantly reduced the nicotine induced up-regulation of the pro-angiogenic factor (Zhang et al., 
2007). Comparable effects have also been observed in gastric cancers by up-regulating both COX2 
and VEGF-receptors in response to nAChR stimulation (Shin et al., 2005).  
Once established, malignant tumour cells begin a process of local invasion and formation of 
distant colonies, termed metastasis. Cancer cells of the primary tumour follow a sequence of key 
events that characterise the process of metastasis. First, the cells invade the surrounding tissue, and 
enter the microvasculature of the lymph and blood systems (intravasation). The cancer cells then 
migrate from the bloodstream into distant tissues (extravasation), where the cells must adapt to the 
new environment in order to form new colonies and proliferate (Chaffer et al., 2011). An integral 
process in tumour metastasis is the ability of cancer cells to undergo the epithelial-mesenchymal 
transition (EMT). EMT is a mechanism by which cancer cells lose their endothelial characteristics 
and develop a more migratory mesenchymal phenotype, stimulating invasion and migration. The 
initiation of EMT involves the action of several transcription factors that regulate genes involved in 
the migratory process, allowing cancer cells to down-regulate adhesive junctions with neighbouring 
cells and intravate the local vasculature (Grando, 2014). 
Signalling through α9-containing nAChRs is critical in the migration of several cancer cell 
types. The expression of the α9 subunit in breast cancer cell lines, MCF-7 and MDA-MB-231, 
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increases cell migration in response to nicotine; while the effects are blocked through the selective 
inhibition of the α9 subunit both in vitro and in vivo (Hung et al., 2011; Lee et al., 2010). The 
stimulation of α9-containing nAChRs results in the phosphorylation of several adhesion and 
intercellular junction proteins, such as FAK, paxillin and β-catenin, key steps in the EMT 
(Chernyavsky et al., 2007). Furthermore, the proinvasive effects of nAChRs have been linked to 
α7-subunit expression on NSCLCs, breast cancer and pancreatic cancer cell lines. Nicotine 
stimulation of the receptor facilitated cellular invasion across all cell lines, and most importantly 
induced changes in gene expression consistent with the EMT. The reduction in epithelial markers, 
such as E-cadherin, and the increased expression of mesenchymal proteins, such as vimentin and 
fibronectin, in response to nAChR stimulation, further validate the role of nAChRs in the EMT and 
tumour metastasis (Dasgupta et al., 2009). 
1.2.4 Anti-Apoptotic Effects of nAChRs in Cancer Survival 
Apoptosis serves as a natural barrier against the development of cancerous cells. Some of the 
notable signals that induce apoptosis include uncontrolled cellular signalling and DNA damage, 
both of which are essential precursors to the development of cancer. The intracellular activation of 
apoptosis is controlled by the balance of pro- and anti-apoptotic regulator messengers, that when 
altered towards a pro-apoptotic state, induce a cascade of downstream effectors that result in 
programmed cell death. One family of anti-apoptotic molecules, the Bcl-2 family, are of particular 
relevance to cancer. Bcl-2 acts as an inhibitor of apoptosis, by binding to and suppressing the 
effects of the pro-apoptotic proteins Bax and Bak. When activated, the Bax and Bak proteins disrupt 
the outer mitochondrial membrane, causing the release of pro-apoptotic factors, such as cytochrome 
c, that induce the cascade of proteolytic caspases, resulting in apoptosis. Overexpression of Bcl-2 in 
cancer cells inhibits the downstream effector molecules of apoptosis, thus allowing the cancer cells 
to continue to proliferate (Adams et al., 2007; Hanahan et al., 2011). 
Recent studies into the effects of nicotine on human MCF10A and MDA-MB-231 breast 
cancer cells have shown an association between nAChR activation and Bcl-2 expression. Treatment 
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of breast cancer cells with 0.5 μM nicotine for 48 hours produced a significant 2-fold increase in 
Bcl-2 expression, coinciding with a 2-fold increase in cell colony formation. Interestingly, the 
increase in expression of Bcl-2 was inhibited by the co-administration of KP372-1, a selective Akt 
inhibitor. The inhibition of Bcl-2 up-regulation in the presence of nicotine was again reflected in the 
number of cancer cell colonies, with the number of colonies returning to baseline in the presence of 
KP372-1. The results demonstrated that persistent activation of nAChRs induces an up-regulation in 
Bcl-2, enhancing cancer cell survival through the induction of anti-apoptotic pathways, with the 
effects regulated by the intracellular messaging of the Akt pathway (Nishioka et al., 2011). 
Additional studies have further added to the role of nAChR in inducing Bcl-2 expression, with 
nicotine treatment significantly prolonging cell survival and protecting breast cancer cells against 
doxorubicin induced cell death through mechanisms involving Bcl-2 phosphorylation (Mai et al., 
2003). 
Similar increases in Bcl-2 expression of various other cancer cell types have been observed 
following nAChR activation. Human colorectal cancer cell lines treated with 1 μM nicotine induced 
a significant increase in phosphorylated Akt and Bcl-2. Further investigation into the specific 
nAChR subtypes involved in this process found that co-treatment with α-Bungarotoxin, a selective 
α7-nAChR antagonist, inhibited both cell growth and the anti-apoptotic pathways (Cucina et al., 
2012). Similarly, the anti-apoptotic activity of human bronchial epithelial cells is thought to be 
mediated via the expression of α3-, α4- and α7-containing nAChRs, resulting in the downstream 
activation of the Akt pathway (West et al., 2003). Exposure of lung epithelial and cancer cells to 
nicotine and nicotine-derived nitrosamines promotes cell survival through the increased expression 
of Bcl-2, complemented by an increased resistance to cisplatin-induced apoptosis. Comparable 
effects were observed between the healthy lung epithelial cells and the cancer cells, further 
consolidating the idea that nAChRs play a key role in the development of cancer through the 
induced expression of anti-apoptotic factors (Nishioka et al., 2010). 
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1.2.5 nAChRs and Cancer Cell Death 
The anti-apoptotic effects of nAChRs in cancer survival are well defined in current literature. 
nAChR stimulation during cancer development induces the Akt signalling pathway, increasing the 
phosphorylation of the known anti-apoptotic messenger, Bcl-2. These anti-apoptotic effects of 
nAChRs expressed on various cancer cell types have been discussed. However, the relationship 
between nAChR blockade via antagonists and the apoptotic activity of cancer cells is less well 
defined by the current literature.  
Recent studies have demonstrated that various lung cancer cell lines express all the functional 
components of the ACh autocrine pathway, including acetylcholinesterase (AChE), choline 
acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT) and choline transporter 1 
(CHT1). The complete functional loop of ACh signalling allows cancer cells to promote 
proliferation through the autocrine activation of the nAChRs (Lau et al., 2013; Song et al., 2008). 
Lau and colleagues investigated the possible pro-apoptotic effects of inhibiting the ACh autocrine 
pathway in bronchioalveolar carcinoma cells. Initially, A549 and H358 cells treated with 100 nM 
nicotine demonstrated a significant increase in cancer cell ACh secretion, through the up-regulation 
of VAChT and ChAT, acting specifically through the α7-, α3β2 and β3-containing nAChR 
subunits. The increase in AChR-related enzymatic activity and cell signalling coincided with an 
increase in bronchioalveolar carcinoma cell proliferation. The carcinoma cells were then co-treated 
with 50 μM vesamicol, a VAChT antagonist, to investigate whether the nicotine-ACh induced 
growth of human bronchioalveolar carcinoma cells could be alleviated. Vesamicol caused 
significant apoptosis in A549 and H358 cells, with a 2.5 to 3-fold increase in apoptosis relative to 
nicotine-only treated carcinoma cells. The pro-apoptotic effects of vesamicol were linked to a 
significant decrease in phosphorylated Akt. The findings can be explained by decreasing nAChR 
activation swaying the balance of apoptotic mediators towards a pro-apoptotic state, thus inducing 
cancer cell death (Lau et al., 2013). 
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 The homomeric α7 nAChR is of particular interest given its abundant expression and well-
established role in the activation of signalling transduction pathways with anti-apoptotic and 
proliferative effects. APS8, a polymeric alkypyridinium salt, was investigated by (Zovko et al., 
2013) for its ability to induce NSCLC cell apoptosis through selective antagonistic binding to α7 
nAChRs. APS8 showed a concentration dependent decrease in lung cancer cell viability (IC50 = 
~370 nM), while having little effect on normal fibroblast cells. The decrease in cancer cell viability 
was correlated with a prominent induction of apoptotic morphology, with ~40% of cells found to be 
apoptotic following exposure to 500 nM of APS8 for 48 hours. Radioligand displacement studies 
demonstrated that the pro-apoptotic effects were mediated via antagonising the α7 nAChRs through 
displacing the specific binding of 125I-α-BTX to the receptors. The effects of APS8 on a number of 
apoptotic proteins was also investigated using a Human Apoptosis Antibody Array. APS8 induced 
the up-regulation of several pro-apoptotic proteins, including bad, bax, cytochrome C, SMAC, 
TRAIL-R1, Fas, and various caspases, while down-regulating anti-apoptotic proteins, such as Bcl-2 
and Bcl-W. The ratio between the levels of bax and Bcl-2 proteins determines whether apoptosis 
will be induced, with an increase in the bax/Bcl-2 ratio causing a switch towards mitochondrial 
membrane permeabilisation and activation of apoptosis. Therefore, the change in bax and Bcl-2 
expression following α7 nAChR antagonism may facilitate the observed APS8 induced cancer cell 
death (Zovko et al., 2013). Given the effects of agonists and antagonists of nAChR in controlling 
cellular growth, they are being explored as potential therapeutics for a number of diseases. 
 
1.3 nAChR-Modulators and nAChR-Based Therapies 
An improved understanding of various neurological and inflammatory diseases has implicated 
the potential role of nAChRs in these conditions. Furthermore, the differences in the expression 
pattern of the various nAChR subtypes within a disease state allows for selective pharmacological 
targeting of these receptors. The following section explores some of the nAChR-modulators being 
developed to target a number of nAChR-associated diseases.  
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1.3.1 nAChR-Based Therapies for Common Diseases 
Agonists of α7-nAChRs have been identified as pharmacologically relevant compounds for 
the treatment of several neuronal or inflammatory associated diseases. Examples of nAChR-
modulators currently under investigation for use in various disease states, as reviewed by (Pohanka, 
2012), are presented in Table 1. The association between α7 nAChRs and the accumulation of 
Amyloid β peptide within the CNS of Alzheimer’s patients has been well characterised. The 
development of agonists to target the nAChR subtype has shown promise in the treatment of 
Alzheimer’s disease by inducing neuroprotection and slowing disease progression (Lombardo et al., 
2014). A potent α7 nAChR agonist, SEN1233, is of current interest due to its ability to cross the 
blood brain barrier when administered orally, thus alleviating some of the common problems 
associated with current CNS-associated treatments. ABT-107, another agonist of α7 nAChR has 
shown promise in the treatment of Alzheimer’s disease through protecting rat cortical cultures from 
glutamate induced toxicity (Pohanka, 2012).  
The use of α7 nAChR modulators in the treatment of schizophrenia is another avenue of 
current research. Reduced levels of α7-subtype expression have been observed in the post-mortem 
brains of schizophrenic patients (Martin-Ruiz et al., 2003). GTS-21, a partial α7 nAChR agonist, is 
one of the most commonly explored treatments for schizophrenia. Clinical studies of GTS-21 have 
reported improvements in neurocognitive function and gating of P50 auditory evoked potentials in 
schizophrenic patients (Olincy et al., 2006). Promising results have also been observed in 
schizophrenic models with another full agonist of the α7 nAChRs, TC-5619; however, these 
compounds currently have limited clinical ability (Lieberman et al., 2013). Nevertheless, studies 
demonstrating an improvement of cognition in schizophrenic patients following nicotine treatment 
reinforce the possibility of developing selective nAChR treatments (Young et al., 2013).  
The development of compounds that target the anti-inflammatory pathways of the cholinergic 
system is another emerging area of therapeutic drug research. Several diseases associated with an 
overstimulation of the immune system have led to the theory that pharmacological targeting of the 
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cholinergic anti-inflammatory pathways may alleviate disease symptoms and progression (Pohanka, 
2012). The GTS-21 compound, currently being investigated in the treatment of schizophrenia, also 
has implications in preventing inflammatory injury through reducing TNF-α and the production of 
other pro-inflammatory cytokines (Rosas-Ballina et al., 2009). Vc1.1, an α9-nAChR modulator, has 
demonstrated clear analgesic effects in a variety of animal pain models with encouraging pre-
clinical results (Livett et al., 2006). Another compound, CNI-1493, is a potential pro-inflammatory 
cytokine inhibitor via its selective binding to the α7 nAChR. CNI-1493 has been investigated 
clinically for use as a treatment in Crohn’s disease, with chronic dosing having positive effects on 
disease progression (Dotan et al., 2010). Selective α7 nAChR agonists may also have implications 
in other clinical conditions of the digestive tract, such as in the treatment of postoperative ileus. The 
α7 agonist, AR-R17779, potently prevents postoperative ileus in mice, restoring the propulsive 
function of the entire gastrointestinal tract following abdominal surgery (The et al., 2007). Although 
considerable promise with α7 nAChR compounds has been demonstrated in the laboratory, there 
are currently no clinically approved drugs that target the cholinergic system of neurological and 
inflammatory pathways.   
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Table 1: Examples of Selective α7 nAChR-Modulators Investigated for the Treatment of Various 
Disease States 




Tested for the treatment of Alzheimer’s 
disease and cognitive deficits associated 









Vc1.1 Peptide structure similar to α-conotoxin 
Potential analgesic effect for the 






Investigated under clinical trials (as 
Semapimod) for its ability to inhibit 





Under clinical testing for the treatment 
of Alzheimer’s, cognitive deficits 





Preclinical testing to prevent 
postoperative ileus following abdominal 
surgery. 
 
1.3.2 nAChR-Modulators for Cancer Treatment 
The connection of nAChRs with cancer development is well established with various nAChR 
subtypes contributing to tumour proliferation, survival and metastasis. Antagonism of the nAChRs 
has the potential to inhibit these effects and induce cancer cell apoptosis, as discussed in Section 
1.2.5 nAChRs and Cancer Cell Death. Many experimental compounds, including those investigated 
for the use in various disease states, may also have important implications in cancer treatment. The 
following section explores the novel compounds used to selectively target the nAChR pathway to 
regulate cancer development. 
Overexpression of the nAChR in human NSCLC tissues has led to a number of studies 
attempting to modulate the nAChRs to limit tumour progression.  MG624, a synthetic α7-nAChR 
antagonist has displayed both anti-proliferative and anti-angiogenic properties in SCLC. Human 
microvascular endothelial cells derived from the lung (HMEC-L) co-treated with both MG624 and 
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nicotine supressed the nicotine-associated proliferation of the cancer cells, consolidating the 
nAChR-action of MG624. In vivo studies administering MG624 in a SCLC tumour xenografted 
murine model demonstrated potent anti-angiogenic effects, supressing angiogenesis through 
reducing both EGR-1 and FGF2 promoters (Brown et al., 2012; Thornhill et al., 2013). Similar 
effects have also been observed when co-administering the α7-nAChR antagonist, α-BTX, with 
cisplatin (alkylating-like chemotherapy drug). The cytotoxic effectiveness of α-BTX alone and in 
combination with cisplatin was investigated in A549 lung adenocancer and SK-MES-1 lung 
squamous cells. The combination of 0.1 μM cisplatin with low levels of α-BTX (1.0 ρM) 
significantly increased the expression of the apoptotic factors Bax, and Caspase-3, while decreasing 
Bcl-2 expression, compared to individual treatment (Balkan et al., 2012). 
Naturally occurring compounds have been implicated as possible anticancer treatments due to 
their interaction with the overexpressed α9-nAChRs in breast cancer. The green tea-polyphenol (–)-
epigallocatechin-3-gallate (EGCG) has been explored as a nAChR-blocker of nicotine or estradiol 
(E2) induced breast cancer proliferation. MCF-7 human breast cancer cells pre-treated with EGCG 
completely abolished the nicotine and E2 induced α9-nAChR activity. Co-treatment with EGCG 
also inhibits the binding activity of 3H-nicotine to the α9-nAChRs of breast cancer cells. EGCG 
(1 μM) was shown to competitively bind the α9-nAChR and induce receptor down-regulation, 
reducing the nAChR proliferative effects of nicotine and E2 (Tu et al., 2011). Continual studies 
have compared additional green and black tea extracts to the inhibitory effects of EGCG α9-
nAChRs. Human breast cancer cells with different ER status, MDA-MB-231 (ER–) and MCF-7 
(ER+) were pre-treated with the extracts, having prominent effects on the inhibition of nicotine-
induced α9-nAChR protein expression. Extract treatment also inhibited colony formation of MCF-7 
cells, with some extracts demonstrating a higher degree of α9-nAChR regulation than that observed 
by EGCG treatment (Ho et al., 2013). Similar results have also been observed with studies treating 
MDA-MB-231 cells with polyphenolic compounds, luteolin and quercetin, by significantly down-
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regulating α9-nAChR expression (Shih et al., 2009). The results demonstrate the potential of diet-
based extracts as possible natural modulators of the α9-nAChRs to limit cancer progression. 
In addition to the naturally occurring polyphenols, various endogenous compounds have 
demonstrated the potential to regulate nAChR activity.  The endogenous secreted mammalian Ly-
6/urokinase plasminogen activator receptor-related protein-1 and -2 (SLURP-1 and SLURP-2), 
responsible for signal transduction, immune activation and cell adhesion, has shown α7-nAChR 
positive allosteric functions with possible anti-carcinogenic properties (Pettersson et al., 2009). 
HT29 human colon carcinoma cells incubated with 1 μM of SLURP-1 and SLURP-2 significantly 
reduced cell numbers by ~54 and 63%, respectively, compared to controls. Neither necrotic nor 
apoptotic cell death was observed following fluorescent microscopy, with the researchers 
concluding that the anti-proliferative effects of SLURP-1 and SLURP-2 were manifested through 
the interactions with the α7-nAChR (Lyukmanova et al., 2014). The endogenous neurotransmitter, 
serotonin (5-hydroxytryptamine, 5-HT), also displays possible anti-carcinogenic activity with links 
to nAChR function. Treatment of HT29 and LS1034 carcinoma cells with the selective serotonin 
reuptake inhibitor, sertraline, induced caspase-3 activation and Bcl-2 inhibition, causing a dose-
dependent decrease in cancer cell viability. In vivo, sertraline significantly inhibited tumour growth 
in CD1 nude mice xenografted with HT29 cells (Gil-Ad et al., 2008). While the effects of serotonin 
reuptake inhibitors have been shown to eliminate the effects of nicotine and nicotine-derived 
nitrosamines, suggesting a link between increased serotonin levels and nAChR inhibition (Schuller, 
2009). 
The use of nAChR modulators as possible cancer sensitisers to current chemotherapy drugs 
has been investigated. The nAChR antagonist adiphenine (ADI) was investigated in combination 
with the chemotherapy drugs, doxorubicin and docetaxel. A vast range of cancer cell lines were 
explored, with cell lines grouped according to their sensitivity (based on the IC50 value from the 
chemotherapy treatment) to discriminate between drug-sensitive and -resistant cell lines. 250 μM 
ADI treatment of resistant breast carcinoma cell lines did not affect cell proliferation; however, 
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when combined with 0.1 μM doxorubicin + 100 μM docetaxel treatment, caused a significant ~40% 
reduction in cell viability, compared to doxorubicin + docetaxel treatment alone. The sensitising 
effects were observed at 4-fold lower doses of ADI, even when combined with half of the 
doxorubicin + docetaxel dose. Similar effects were also observed with the nAChR antagonists 
proadifen and NDNI. The researchers claimed that the chemo-sensitising effects of the nAChR 
antagonists were operating through the α9 subunit, having the potential to reduce the amount of 
toxic chemotherapy agents required to induce tumour cell death in vivo (Hallett et al., 2012). 
Neurotoxins, commonly used to distinguish between nAChR subunit combinations through 
their selectivity to distinct receptor configurations, demonstrate potential cancer modulating effects. 
Studies have suggested that cancer cell proliferation can be arrested through the use of snake 
neurotoxins or snail conotoxins due to their selective antagonistic effects at the α7 nAChRs (Wu et 
al., 2011). One particular toxin of interest, α-cobratoxin (α-CbT), has produced anticancer effects in 
various cancer cell models, both in vitro and in vivo. The treatment of mesothelioma MPP89 cells 
showed a notable induction of apoptosis following treatment with α-CbT, significantly inducing 
caspase-3 cleavage and down-regulating several anti-apoptotic proteins (survivin, XIAP, IAP1, 
IAP2 and Bcl-xl). In vivo, orthotopically transplanted NOD/SCID mice treated with a 1/1000 LD10 
dose of α-CbT (0.12 ng/kg) significantly reduced tumour growth without any signs of significant 
toxicity to healthy cells (Catassi et al., 2008). Comparable effects have also been observed in A549 
NSCLC orthotopically grafted nude mice and MCF-7 breast tumour-bearing nu/nu mice following 
treatment with α-CbT (CATASSI et al., 2006; Mei et al., 2015). 
1.3.3 Marine Toxins 
The potential anticancer effects of various marine-derived agents has been long known, with 
several compounds approved for the use in treating various human cancers, including cytarabine, 
eribulin and monomethylauristatin E (Newman et al., 2014). However, the discovery of marine 
toxins that have regulatory effects on the nAChR-system has been a new avenue for marine-derived 
anticancer therapeutic research. One of the first marine toxins investigated for their potential 
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anticancer effects were the polymeric alkylpyridinium salts (poly-APS), isolated from the marine 
sponge Reniera sarai, for their AChE inhibitory activity. Fluorescence-activated cell sorting 
analysis of NSCLC cells treated with poly-APS showed a selective cytotoxicity of the marine salts 
towards cancer cells, compared to normal lung fibroblasts. Non-toxic doses of poly-APS also 
reduced NSCLC cell-to-cell adhesion in vitro, while having no significant organ toxicity in healthy 
C57BL/6N mice. The study indicated the possibility of regulating cancer cell proliferation through 
the cholinesterase inhibitory effects of marine toxins (Paleari et al., 2006). 
Since the discovery of poly-APS, several toxins have been extracted from marine shellfish 
that act directly on nAChRs, possessing both potent and selective properties. Extracts related to the 
cyclic imine group of toxins, such as gymnodimine (GYM) and spirolides, potently antagonise both 
homomeric and heteromeric nAChRs (Bourne et al., 2010). Pinnatoxin (PnTX), a newly discovered 
group of cyclic imines, has demonstrated high antagonistic affinity towards α7-nAChR. Recordings 
of gamma oscillations in response to tetanic stimulation of hippocampal CA1 slices of male 
Sprague-Dawley rats showed a reduction in gamma pulse shape discrimination and spike count in 
the presence of PnTX E and F, similar to that seen with the selective α7 nAChR antagonist 
methyllycaconitine (Hellyer et al., 2011). Furthermore, studies suggest that cyclic amines 
specifically target the α7-subtype, with relatively less potent effects at the heteromeric subtypes, 
such as α4β2-nAChRs (Hellyer et al., 2011; Kharrat et al., 2008). The potential nAChR-
antagonistic effects of pinnatoxins suggest their possible use in elucidating the contribution of 
nAChRs to cancer development and as therapeutics for regulating cancer cell proliferation. 
 
1.4 Aims and Hypothesis 
Current literature has identified the various nAChR pathways that contribute to the 
development of cancer. The majority of the published studies focus on the effects of nAChR 
agonists, such as nicotine, on enhancing the carcinogenic properties of various lung, breast and 
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colon cancer cell lines. However, investigation into the role of nAChRs in the development of 
glioblastoma is limited.  
Recent studies investigating the use of nAChR antagonists for regulating cancer development 
have highlighted the possible advantages of targeting these receptors directly. The use of these 
antagonists has often been investigated in the presence of nicotine, where the main effects of the 
investigational compounds are to negate the effects of nicotine on progressing cancer development. 
However, many carcinoma cell types, such as mesothelioma and colon cancer types, display an 
increase in nAChR expression independent of exogenous influence from compounds such as 
nicotine (Egleton et al., 2008). These carcinoma cell types also contain the complete functional loop 
of ACh signalling that allows cancer cells to promote proliferation through the autocrine activation 
of nAChRs (Lau et al., 2013; Song et al., 2008). The present study looked to target these 
endogenous functions of nAChRs using a range of pilot studies to better understand the mechanism 
behind nAChR antagonist-induced cancer cell death, where clinical application of the compounds is 
not an immediate focus of the various investigations performed. 
In this research, the effects of both established and novel nAChR antagonists in regulating 
carcinogenesis have been explored directly, and in combination with common chemotherapy 
agents, utilising a variety of different methods. GYM and PnTX are considered novel compounds 
due to the lack of published literature relating to their effects on carcinogenesis. Details regarding 
the various compounds, selectivity towards nAChRs and the concentration ranges investigated have 
been provided in Table 3 (Section 2.2.2. Cell Viability Assay). Specifically the aims of this research 
were: 
 
Aim I: To examine the cytotoxic effects of nAChR modulators on a variety of carcinoma cell 





Aim II: To investigate the mechanism(s) of the newly identified role of nAChR modulators in 
inducing carcinoma cell death.  
 
Aim III: To determine whether inhibiting common apoptotic pathways would reduce the 
cytotoxic effects of nAChR modulators. 
 
Aim IV: To explore the synergistic capacity of the most effective nAChR modulators 
identified in Aims I-III to sensitise cancer cells to common chemotherapy agents.  
 
The results of this research suggest a possible mechanism for nAChR antagonist induced cancer cell 
cytotoxicity, as highlighted in the following sections. The implications of which are discussed in 





2.1 Cell Culture 
2.1.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), foetal bovine serum (FBS), 0.5% Trypsin 
EDTA, and Penicillin/Streptomycin were purchased from Gibco, Life Technologies (California, 
USA). Phosphate buffered saline (PBS) was purchased from Invitrogen, Life Technologies 
(California, USA). Haemocytometer, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and Roswell Park Memorial Institute (RPMI) 1640 Medium was purchased from Sigma-
Aldrich (St Louis, MO, USA). Dimethyl sulfoxide (DMSO) was purchased from Scharlau 
(Sentmenat, Barcelona, Spain). GraphPad Prism 5 was purchased from GraphPad Software (La 
Jolla, CA, USA). 
2.1.2 Cell Lines and Cell Culture 
A total of eight human carcinoma cell lines were used in this research, as described in Table 
2. MDA-MB-231, SKBR3, HT29 and PC3 cell lines were a gift from Associate Professor R. 
Rosengren of the Pharmacology Department, University of Otago (Dunedin, NZ). U87, U373 and 
LN18 cell lines were a gift from Dr. K. Greish of the Pharmacology Department, University of 
Otago (Dunedin, NZ). A549 cells were a gift from Dr. G. Giles of the Pharmacology Department, 
University of Otago (Dunedin, NZ). 
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Table 2: Details of the Carcinoma Cell Lines 
Cell Line Disease State Cell Type Tissue 
MDA-MB-231 Breast adenocarcinoma Epithelial 
Mammary gland/breast, 
derived from metastatic 
site (pleural effusion) 
HT29 Colorectal adenocarcinoma Epithelial Colon 
PC3 
Grade IV prostate 
adenocarcinoma 
Epithelial 
Prostate, derived from 
metastatic site (bone) 
SKBR3 Breast adenocarcinoma Epithelial 
Mammary gland/breast, 
derived from metastatic 
site (pleural effusion) 
A549 Lung carcinoma Epithelial Lung 
U87 Grade IV astrocytoma Epithelial Brain 
LN18 Grade IV astrocytoma Epithelial 
Brain/cerebrum, right 
temporal lobe 
U373 Grade IV astrocytoma Epithelial Brain 
 
MDA-MB-231, HT29, PC3, A549 and SKBR3 cells were cultured in DMEM with 10% heat 
inactivated FBS, 100 units/mL penicillin and 100 µg/mL streptomycin. U87, U373 and LN18 cells 
were cultured in RPMI medium with 10% heat inactivated FBS. Cells were incubated at 37°C in 
5% CO2 humidified conditions. Cell lines grew to ~80% confluence in 75 cm
2 culture flasks before 
passaging. The sub-culturing process involved discarding the media, washing with 2 mL trypsin 
solution (1x trypsin, 0.5% EDTA, PBS), and incubated in 2 mL trypsin solution until cells no 
longer adhered. 5 mL fresh media was added to the trypsin-cell solution, transferred to a 15 mL 
falcon tube and centrifuged at 1200 rpm for 3 minutes at 4°C. The supernatant was discarded, with 
the cell pellet re-suspended in 5 mL fresh medium. Cells were counted visually using a 
haemocytometer under 20x magnification. The number of cells were counted in all four quadrants, 
averaged and multiplied by 104, to give the cell number per mL of media. Cells were then seeded 
according to experiment requirements. 
2.1.3 MTT Assay 
The MTT colourmetric assay was employed to determine cell viability following treatment 
(refer below). The assay utilises the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) (MTT) by NAD-dependant enzymatic activity, to form formazin crystals, as 
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an indicator of metabolically active viable cells (Mosmann, 1983). The MTT solution was prepared 
at 5 mg/mL in PBS and combined with cells at a final concentration of 0.5 mg/mL. The MTT-media 
solution was incubated for ~3 hours in the humidified incubator, solution removed, and replaced 
with an equal volume of DMSO (to dissolve the formazin crystals, forming a purple solution). The 
reduced MTT solution was analysed spectrophotometrically at 560 nm and processed using 
microplate manager 5.2.1 software to quantify the amount of viable cells. 
2.1.4 Statistical Analysis 
For all cellular viability MTT assay results, GraphPad Prism software was utilised to average 
and normalise the absorbance values as a percentage of the control mean ± the standard error of the 
mean (SEM) following technical replicates of the method. Significance was determined by 
analysing the difference of the means, using either a one-way or a two-way analysis of variance 
(ANOVA) with a Bonferroni post-hoc test, where the p-value between the compared groups was 
less than 0.05 (p<0.05). 
 
2.2 Cell Viability Assay 
2.2.1 Materials 
Acetylcholine chloride, (–)-nicotine hydrogen tartrate salt, methyllycaconitine citrate, 
serotonin creatine sulphate complex, adiphenine hydrochloride and isopropanol were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Mecamylamine hydrochloride was purchased from 
Abcam (Cambridge, UK). Pinnatoxin G and Gymnodimine were gifted from Assoc. Prof. S. Kerr of 
the Pharmacology Department, University of Otago (Dunedin, NZ), and Dr Paul McNabb and Dr 
Andrew Selwood of the Cawthron Insititute (Nelson, NZ). 
2.2.2 Cell Viability Assay 
MDA-MB-231, HT29, PC3, U87, U373 and LN18 cell lines were seeded in 96-well plates at 
a density of 3,000 cells/100µL/well in their respective media, 24 hours prior to treatment. Cells 
were treated with acetylcholine (ACh), nicotine (NIC), mecamylamine (MECA), pinnatoxin G 
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(PnTX), gymnodimine (GYM), methyllycaconitine (MLA), adiphenine (ADI) or serotonin (5-HT) 
at final well concentration ranging from 0.1 µM to 1000 µM. The vehicle control contained the 
highest concentration of the solvent for the corresponding treatment. Treatment profiles are 
displayed in Table 3. Treated cells were analysed by MTT assay at 24, 48 and 72 hours post 
treatment. The absorbance values for the treated samples were normalised against the untreated 
group for each corresponding time point prior to statistical analysis. 
Table 3: Cell Viability Assay Treatment Profile 
























H2O 10 0.1 1000 
Pinnatoxin G α7, α4β2 Antagonist Isopropranolol 0.193 0.1 5 
Gymnodimine 
α7, α4β2, α3β2 
Antagonist 
H2O 10 0.1 50 
Methyllycaconitine α7 Antagonist H2O 10 0.1 100 
Adiphenine 









H2O 10 0.1 1000 
 
 
2.3 Western Blot 
2.3.1 Materials 
Albumin from bovine serum (BSA), 3-(N-morpholino) propanesulfonic acid (MOPS), 
Tween® 20, sodium dodecyl sulphate (SDS), Trizma®-base, Trizma®-hydrochloride, Triton® X-100, 
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2-mercaptoethanol (MeSH) and tetramethylethylenediamine (TEMED) were purchased from 
Sigma-Aldrich (St Louis, MO, USA). 30% acrylamide/bis solution 19:1 and ammonium persulfate 
(APS), were purchased from Bio-Rad Laboratories Ltd (Hercules, CA, USA). 
Ethylenediaminetetraacetic acid as purchased from BDH/VWR International Ltd (Radnor, PA, 
USA). PageRuler™ Prestained Protein Ladder, CL-XPosure Film, Pierce® Protein Inhibitor Tablets, 
Pierce® BCA Protein Assay Kit, and dithiothreitol (DTT) were purchased from Thermo-Fisher 
Scientific (Waltham, MA. USA). NuPage LPS Sample Buffer and iBlot® Gel Nitrocellulose transfer 
Stacks were purchased from Novex, Life Technologies (California, USA). Amersham ECL Prime 
Western Blotting Detection Reagents were purchased from GE Healthcare (Little Chalfont, UK).  
2.3.2 Antibodies 
Rabbit monoclonal anti-nicotinic acetylcholine receptor alpha 4 antibody, rabbit polyclonal 
anti-nicotinic acetylcholine receptor alpha 7, rabbit polyclonal anti-CHRNA9 antibody (alpha 9), 
goat polyclonal secondary antibody to mouse IgG, and goat polyclonal secondary antibody to rabbit 
IgG were purchased from Abcam, Inc (Cambridge, UK). Mouse monoclonal anti-β-actin antibody 
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The primary anti-α4-
nAChR, anti-α7-nAChR, and anti-β-actin antibodies were used at 1:25,000 dilution; while primary 
anti-α9-nAChR was used at 1:12,500. The secondary antibodies were incubated at 1:10,000 
dilution. Antibodies were diluted in 10 mL PBS containing 1% w/v BSA and 0.1% v/v Tween. 
2.3.3 Protein Extraction 
MDA-MB-231, HT29, PC3, U87, U373 and LN18 cell lines were seeded in 6-well plates at a 
density of 200,000 cells/mL/well in their respective media. For baseline levels of nAChR 
expression, cells were grown until ~80% confluence before harvesting. Treated samples were 
allowed to adhere for 24 hours prior to treatment, and then harvested 72 hours post treatment, with 
appropriate untreated controls. MDA-MB-231 cells used in the time-course study were treated after 
24 hour adherence with 10 µM nicotine, and harvested at 30 min, 60 min, 2 h, 6 h, and 24 h post-
treatment, with corresponding untreated controls. Cell samples were harvested by removing media, 
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washing with PBS and incubating in 200 µL lysis buffer (NaCl 150 mM, Tris Base 50 mM, SDS 
0.05%, Triton X100 1%,  AEBSF, aprotinin, bestatin, E64, leupeptin, pepstatin A, pH 8.0) on ice 
for 30 min. Cell lysate samples were collected, sonicated, and homogenised by centrifugation 
(18,000 rpm, 8 min, 4°C). The protein concentration of the lysate supernatant was measured using 
the Pierce® BCA Protein Assay Kit, combined with loading buffer, reducing buffer (DTT 500 mM) 
and heat denatured at 70°C for 10 min.  
2.3.4 Western Blotting 
Loading of 5 µg protein per 20 µL per well and protein reference ladder (7 µL per well) was 
resolved by 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis in MOPS buffer 
(MOPS 50 mM, Tris Base, 50 mM, SDS 1%, EDTA 1 mM, pH 7.7) at 150 V for 65 min. Resolved 
proteins were electroblotted onto a nitrocellulose membrane (20 V for 1 min, 23 V for 4 min, 25V 
for 2 min) and blocked (5% nonfat milk solution in PBS-Tween 0.1%) for 100 min at room 
temperature. The membranes were then incubated in the anti-nAChR primary antibody overnight at 
4°C with gentle agitation, washed in PBS-Tween 0.1% (6 x 5 min), and incubated in the appropriate 
secondary antibody at room temperature for 60 min. Membranes were washed as described above, 
visualised with enhanced chemiluminescence reagent (used at a 1:1 concentration, as per the 
manufacturer’s instructions) and immediately exposed to X-ray film for developing. The 
membranes were then stripped (Tris HCl 62.5 mM, SDS 2%, MeSH 0.1 M, pH 6.8) for 30 min at 
50°C, washed, blocked and re-probed with anti-β-actin primary antibody (for normalisation of 
loading). Developed films were scanned using an imaging densitometer and densitometry data for 
the individual Western blot bands determined by Quantity One software. GraphPad Prism software 






Paraformaldehyde and Hoechst BisBenzimide H33342 trihydrochloride were purchased from 
Sigma-Aldrich (St Louis, MO, USA). Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) Antibody and 
ProLong® Gold antifade reagent were purchased from Molecular Probes, Life Technologies 
(California, USA).  
2.4.2 Sample  
MDA-MB-231 cells were seeded at 10,000 cells/500µL/well onto sterile micro-circular 
coverslips in 24-well plates for 72 hours. Cells were fixed with 4% paraformaldehyde- PBS pH 7.4 
for 15 min at room temperature. The paraformaldehyde fixed samples were treated with either 
0.25% Triton X-100-PBS (for permeabilisation of cell membranes) or PBS (non-permeabilised) for 
10 min. Following this step, samples were blocked with 1% BSA in PBS-Tween for 30 min, then 
incubated with primary antibody (nAChR-α7 or nAChR-α9 at 1:100 in PBS-Tween) overnight at 
4oC. The probed samples were incubated with fluorescent secondary antibody (488 Goat Anti-
Rabbit at 1:500 in PBS-Tween) for 1 hour under constant oscillation at room temperature in the 
dark. The coverslips were briefly incubated with 1 µg/mL Hoescht stain for 1 min under dark 
conditions, dried, and transferred to microscope slides, bound by ProLong Gold gel for 
preservation. The prepared microscope slides were dried and stored in the dark until visualisation. 
2.4.3 Fluorescence Microscopy 
Cells were visualised using an upright Nikon Eclipse Ni-E Motorised microscope with 
ultraviolet or blue illumination from a mercury fibre illuminator lamp through a 100x Nikon 
florescence oil immersion objective (numerical aperture 1.3). Images were captured using NIS-
Elements Microscope Imaging Software through a 4,6-diamidino-2-phenylindole (DAPI) or 
Fluorescein isothiocynate (FITC) filter. For image adjustments, the captured images were merged 




2.5 Flow Cytometry 
2.5.1 Materials  
Propidium iodide (PI), citric acid and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) were purchased from Sigma-Aldrich (St Louis, MO, USA). Tetramethylrhodamine, ethyl 
ester, perchlorate (TMRE) and Annexin V (Alexa Fluor® 488 conjugate) were purchased from 
Molecular Probes, Life Technologies (California, USA). Di-sodium hydrogen orthophosphate 
(Na2HPO4) and calcium chloride (CaCl2) was purchased from BDH/VWR International Ltd 
(Radnor, PA, USA). Ribonuclease A was purchased from Invitrogen, Life Technologies (California, 
USA). Ethanol and sodium chloride (NaCl) were purchased from Scharlau (Sentmenat, Barcelona, 
Spain). Cisplatin (CDDP) was purchased from Ebewe Pharma (Unterach, Austria). 
2.5.2 Cell Treatment and Staining 
MDA-MB-231, HT29, PC3, and LN18 cell lines were seeded in 6-well plates at a density of 
100,000 cells/mL/well in their respective media. Samples were allowed to adhere for 24 hours prior 
to treatment with either MECA 1000 µM, PnTX 5 µM, ADI 1000 µM,  5-HT 1000 µM or CDDP 
20 µM, with appropriate untreated controls. Cell samples were harvested using trypsin at 72 hours 
post-treatment, and probed using various fluorescent stains, including PI, TMRE, or a combination 
of Annexin V and PI. 
Propidium Iodide 
 Cells were washed in cold PBS and spun at 2000 rpm for 3 min. The samples were fixed by 
discarding the supernatant and mixing the cell plate with 500 µL per tube of 4°C ethanol 70%, then 
stored at 4°C for 30 minutes. The fixed cell solution was washed twice in phosphate-citrate buffer 
(Na2HPO4 0.192 M, Citric Acid 0.004 M), spinning at 2000 rpm for 3 min between each wash. The 
cell supernatant was removed then treated with 50 µL per tube of 100 µg/mL Ribonuclease A, 




The treated cell samples were re-suspended in 500 µL per tube of appropriate media 
following trypsin harvesting. 2 µL per tube of 10 µM TMRE was added to the samples under dark 
conditions, and incubated at 37°C protected from light for 10 minutes. Cell samples were washed in 
PBS, spun at 2000 rpm for 3 min, and re-suspended in 300 µL per tube of media. Stained samples 
were kept on ice, protected from light until analysis. 
Annexin V/PI 
 The cell samples were washed twice in cold PBS, with spinning at 2000 rpm for 3 min, and 
re-suspended in 100 µL per tube Annexin V binding buffer (HEPES 0.1 M, NaCl 1.4 M, CaCl2 25 
mM, pH 7.4). 2 µL per tube Annexin V conjugate and 2 µL per tube of 50 µg/mL PI were added to 
the cell solution and incubated at room temperature for 15 min protected from light. 400 µL per 
tube of additional Annexin V binding buffer was combined to each sample and stored on ice until 
analysis. 
2.5.3 Fluorescence-Activated Cell Sorting (FACS) 
Stained samples were loaded into FACS tubes and run through the FACSCalibur™. Data was 
acquired using CellQuestPro software with an acquisition criteria of 10,000 events per sample, and 
analysed using Flowing Software 2.5.0. The PI cell samples were measured using the yellow 585/42 
nm (FL2-H) detector and analysed to generate cell cycle phase distribution data. The data was gated 
to ensure only single cells were analysed, with the cell cycle phases (sub-G1, Go/G1, S and G2/M)  
determined manually based on the methods described in the literature (Wlodkowic et al., 2011). 
TMRE samples were measured via the same yellow 585/42 nm detector and histograms produced to 
quantify the change in TMRE peaks between control and treated samples. Double-stained, Annexin 
V and PI samples were measured using the green 530/30 nm (FL1-H) and yellow 585/42 nm (FL2-
H) detectors, graphed accordingly on a dot-plot with quadrants for double stain and individual 
stains measured. Values were entered into GraphPad Prism software and analysed using a one-way 




2.6 Intracellular Calcium 
2.6.1 Materials 
Fura-2 acetoxymethyl ester (AM) was purchased from Abcam, Inc (Cambridge, UK). 
Potassium chloride (KCl) was purchased from Scharlau (Sentmenat, Barcelona, Spain). Glucose, 
and sodium bicarbonate (NaHCO3) were purchased from Sigma-Aldrich (St Louis, MO, USA). 
Potassium di-hydrogen orthophosphate (KH2PO4) was purchased from BDH/VWR International 
Ltd (Radnor, PA, USA). Magnesium sulphate (MgSO4) was purchased from Merck Millipore 
(Darmstadt, Germany).  
2.6.2 Fura-2 AM Fluorescence Measurement 
MDA-MB-231, HT29 and PC3 cells were seeded at 40,000 cells/100µL/well in 96-well black 
plates for fluorescence.  Cells were allowed to adhere overnight before being loaded with 100 µL 
per well of 4 µM of the Ca2+ indicator Fura-2 AM (from 1 mM stock in DMSO) in Hanks Balanced 
Salt Solution (HBSS; NaCl 0.137 M, KCl 5.4 mM, Na2HPO4 0.25 mM, glucose 0.01%, KH2PO4 
0.44 mM, CaCl2 1.3 mM, MgSO4 1.0 mM, NaHCO3 4.2 mM) for 60 min in a humidified incubator 
protected from light. The cells were then washed in HBSS and incubated in fresh HBSS 100 µL per 
well for 30 min at room temperature protected from light to allow Fura-2 AM cleavage. Cells 
transfected with Fura-2 were treated with Ach 10 µM, MECA 1000 µM, PnTX 5 µM, GYM 10 
µM, ADI 1000 µM, MLA 100 µM or 5-HT 1000 µM at time = 0 min. Fura-2 fluorescence was then 
measured every minute for the first 20 min, 1 h, 2 h, 4 h, and 6 h post-treatment. Softpro Max 
Software 4.8 was used to determine Fura-2 fluorescence using a fluorescent plate reader at an 
excitation of 340 nm (λ1) and 380 nm (λ2), with an emission of 510 nm, at each time point. The 
fluorescence intensity ratio (R = Fλ1/Fλ2) of Fura-2 fluorescence detected at 510 nm for each time 
point was then calculated, indicating the ratio of Fura-2 in a completely Ca2+-saturated state against 
Fura-2 in a Ca2+-free state. GraphPad Prism software was used to construct time-course graphs of 




2.7 Cell Death Inhibitors 
2.7.1 Materials 
1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid – acetoxymethyl ester (BAPTA-
AM), N-Acetyl-Leu-Leu-Nle-al (ALLN) and N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl 
ketone (zVAD-FMK) were purchased from Abcam, Inc (Cambridge, UK). Cyclosporin A (CsA) 
was purchased from Sigma-Aldrich (St Louis, MO, USA). 
2.7.2 Cell Culture and Inhibitors 
MDA-MB-231, HT29, PC3, and LN18 cell lines were seeded in 96-well plates at a density of 
3,000 cells/100µL/well in their respective media. Cells were allowed to adhere for 24 hours, then 
treated with specific concentrations of various cell death inhibitors, as shown in Table 4, alone and 
in combination with varying concentrations of PnTX, MECA, MLA, ADI or 5-HT. Treated cell 
viability was measured via MTT assay at 48 and 72 hours post-treatment.  
Table 4: Cell Death Inhibitor Treatment Profile 
Cell Line 
Final Well Concentration (µM) 
CsA ALLN BAPTA-AM zVAD 
MDA-MB-231 10 5 1 30 
HT29 1 1 1 20 
PC3 1 5 10 30 
LN18 1 1 0.5 10 
 
2.7.3 Isobologram 
Following treatment of the various cancer cell types with cell death inhibitors, as described in 
Section 2.7.2, an isobologram was constructed to investigate the relationship between CsA and 
MECA in reducing cell viability. MDA-MB-231 cells were seeded in 96-well plates at a density of 
3,000 cells/100µL/well in DMEM. The cells were allowed to adhere for 24 hours before treatment. 
Cells were treated with CsA at a range of 0.1 to 40 µM, MECA at a range of 10 to 1500 µM, and 
combinations of the two (CsA 0.1, 1.0 or 5.0 µM; MECA 100 or 500 µM). The treated MDA-MB-
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231 cells were then analysed by MTT assay 72 hours post treatment. IC50 values for CsA and 
MECA were calculated for the individual compounds and in combination to determine the overall 
cytotoxic relationship between the two compounds. An isobologram was constructed according to 
the methods described by (Tallarida, 2006) from the IC50 values calculated using OriginPro 
software (OriginLab Corporation, MA, USA). 
 
2.8 Combination Therapy 
2.8.1 Materials 
Doxorubicin (DOXO) and Docetaxel (DTX) were purchased from Cayman Chemical Company 
(Michigan, USA). 
2.8.2 Chemotherapy Combination Therapy 
The methods for chemotherapy combination treatment of various cancer cell lines were 
adopted from (Hallett et al., 2012). MDA-MB-231, HT29, PC3, A549 and SKBR3 cells were 
seeded in 96-well plates at a density of 20,000 cells/100µL/well in their respective media. Cells 
were allowed to adhere for 4 hours, followed by compound addition of various concentrations of 
chemotherapy agents and nAChR antagonists, with appropriate vehicle controls. Chemotherapy 
final well concentrations included doxorubicin at 0.1-1.0 µM and docetaxel at 100 µM. After 24 





3.1 Effects of nAChR Antagonists on Cell Viability 
The link between nAChR activation and cancer development is well established. Several 
nAChR subtypes have been shown to contribute to tumour proliferation, survival and metastasis 
(refer to Section 1.2 nAChRs in Cancer Development). To test the hypothesis that the more selective 
modulators of the nAChRs would display the most potent cytotoxic effects, a colourimetric cell 
viability assay was used to measure the effects of exposure of a range of carcinoma cell types (refer 
Table 2) to both established and novel nAChR modulators (Aim I).  
3.1.1 Cell Viability Assay 
Initial experiments were undertaken using the cell viability assay to establish an effective 
modulating concentration for each test compound. Contrary to expectations, the nAChR agonists 
acetylcholine (ACh) and nicotine (NIC) did not exhibit a consistent change in cell viability across 
the range of concentrations studied (0.1 µM to 1000 µM), with the exception of HT29 cells (data 
not shown). ACh and NIC concentrations of 10 µM were therefore chosen based on the observed 
effects on HT29 cells, an established history of increased cancer cell viability and a potential 
modification of nAChR expression observed at this concentration in published studies (Al-Wadei et 
al., 2012; Dasgupta et al., 2009). Following treatment with ACh 10 µM for 72 hours, a significant 
increase (P < 0.001) in HT29 viability was detected, corresponding to a 28.50% increase in cell 
viability compared to untreated control cells (Figure 3A). A similar increase in cell viability was 
seen following treatment of HT29 cells with NIC 10 µM (19.91% increase in cell viability) (Figure 
3B). No significant increase in cell viability was seen in any other cell line when treated with either 
ACh or NIC at 10 µM. Furthermore, visual analysis of MDA-MB-231, HT29 and PC3 cell lines, 
provided for reference only, at 72 hours post treatment showed no changes in cell morphology or 





















24 48 72 
MDA-MB-231 ns ns ns 
HT29 ns ns *** 
PC3 ns ns ns 
U87 ns ns ns 
LN18 ns *** * 
U373 ns ns ns 

















































24 48 72 
MDA-MB-231 ns ns ns 
HT29 ns ns ** 
PC3 ns ns ns 
U87 ns * *** 
LN18 * ns * 
U373 ns ** *** 
































Figure 3: The determination of MDA-MB-231, HT29, PC3, U87, LN18 and U373 cell viability following treatment with 
ACh 10 µM (A) or NIC 10 µM (B). Cells were treated following a 24 hour seeding period, with cell viability tested at 24 
hour intervals over a 72 hour study timeframe, with viability established using the MTT assay. Bright-field microscopic 
images of MDA-MB-231, HT29 and PC3 treated cells (primary image) versus control cells (inset image) at 72 hours 
are shown (20x magnification). Values are displayed as the mean percent of the viability of control (untreated) cells, 
with error bars representing SEM (n = 2). A two-way ANOVA with a Bonferroni post-hoc test was used to determine 







ACh 10 μM 
NIC 10 μM 
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An array of nAChR antagonists were investigated for their effects on cancer cell viability. The 
selectivity of the antagonists towards specific nAChR subtypes ranged from relatively non-selective 
to highly selective, as summarised in Table 3. Again, concentration dependence studies were 
conducted on each compound to determine which concentration had the greatest effect on cell 
viability (data not shown). Contrasting effects on cell viability, compared to ACh and NIC, were 
seen for the majority of compounds tested. Mecamylamine (MECA) 1000 µM, pinnatoxin G 
(PnTX) 5 µM, serotonin (5-HT) 1000 µM and adiphenine (ADI) 1000 µM caused a significant 
decrease in cell viability after 72 hours of treatment for all cell lines tested (P < 0.01 for all 
treatments and cell lines). MECA 1000 µM (Figure 4A) and 5-HT 1000 µM (Figure 4D) produced 
the largest range of viability results; causing a 21.53% (U87) to 83.28% (HT29) and 16.66% (U373) 
to 72.74% (PC3) decrease in cell viability, respectively. ADI 1000 µM (Figure 4E) treatment 
caused at least 50% decrease in cell viability by the 48 and 72 hour time points in all cell lines 
tested, with MDA-MB-231s demonstrating the greatest susceptibility to ADI treatment (97.62% 
decrease in cell viability at 72 hours compared to control). PnTX 5 µM (Figure 4B) was the most 
potent of the antagonists studied, causing between 28.11% (U87) to 68.32% (HT29) decrease in cell 
viability at a concentration 200-fold lower than all other nAChR antagonists tested. Gymnodimine 
(GYM) 10 µM (Figure 4C) and methyllycaconitine (MLA) 100 µM (Figure 4F) produced the least 
significant change in cell viability of the compounds tested. 
Bright-field microscopic images of MDA-MB-231, HT29 and PC3 cell lines, as a 
representation of all the cell lines tested, at 72 hours post treatment showed obvious visual changes 
in cell morphology and confluency, consistent with the viability results. MECA, 5-HT and ADI 
treatment showed a widespread decrease in cell viability, compared to control (untreated) cells. A 
similar change in cell viability was seen following PnTX treatment, with a significant depletion in 
viable cells compared to control cells. Microscopic images following GYM and MLA treatment 


























24 48 72 
MDA-MB-231 *** *** *** 
HT29 *** *** *** 
PC3 *** *** *** 
U87 ns * ** 
LN18 *** *** *** 
U373 * *** *** 





















































24 48 72 
MDA-MB-231 ns ** *** 
HT29 *** *** *** 
PC3 ns *** *** 
U87 *** *** *** 
LN18 *** *** *** 
U373 ** *** *** 
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24 48 72 
MDA-MB-231 ns * ** 
HT29 ns ns ns 
PC3 ns ns ns 
U87 ns ns ns 
LN18 ns ns ns 
U373 ns ns ns 























































24 48 72 
MDA-MB-231 *** *** *** 
HT29 ns *** *** 
PC3 ns *** *** 
U87 *** *** *** 
LN18 *** ns *** 
U373 ** *** *** 
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24 48 72 
MDA-MB-231 *** *** *** 
HT29 *** *** *** 
PC3 *** *** *** 
U87 ns *** *** 
LN18 *** *** *** 
U373 *** *** *** 


















































24 48 72 
MDA-MB-231 ns ns ns 
HT29 ns ns ns 
PC3 ns ns ** 
U87 ns ** ns 
LN18 ns ns ns 
U373 ns ns * 
































Figure 4: The evaluation of MDA-MB-231, HT29, PC3, U87, LN18 and U373 cell viability following treatment with 
MECA 1000 µM (A), PnTX 5 µM (B), GYM 10 µM (C), 5-HT 1000 µM (D), ADI 1000 µM (E) or MLA 100 µM (F). 
Cells were treated following a 24 hour seeding period, with cell viability tested using the MTT assay at 24 hour 
intervals over a 72 hour study timeframe. Bright-field microscopic images of MDA-MB-231, HT29 and PC3 treated 
cells (primary image) versus control cells (supplementary image) at 72 hours are shown (20x magnification). Values 
are displayed as the mean percent of the control viability, with error bars representing SEM (n = 2). A two-way 







ADI 1000 μM 
MLA 100 μM 
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3.1.2 Western Blot - Basal nAChR Levels 
To investigate the possible correlation between nAChR subtype expression and susceptibility 
to nAChR antagonism-induced changes in cell viability, the basal levels of nAChR subtypes in the 
cell lines tested were determined using Western blot analysis. The relative densities of the bands on 
the Western blots were quantified using laser densitometry in comparison to β-actin. 
As described in the literature, the relative abundance of the different nAChR subtypes within 
a cell varies depending on cell type. HT29 cells demonstrated the greatest level of nAChR 
expression across all cell lines, as shown in Figure 5. HT29 cell expression of the α4, α7 and α9 
nAChR subtypes were shown to be at least 142.6%, 7.43% and 86.80%, higher than the expression 
observed in all other cell lines for the respective subtypes. PC3 cells showed a similar level of α7 
nAChR expression as the HT29 cells; while LN-18 possessed the greatest total nAChR expression 











































Figure 5: Western blot analysis showing the basal level of α4, α7 and α9 nAChR expression in MDA-MB-231, HT29, 
PC3, U87, LN18 and U373 cancer cell lines. β-actin protein was used as a loading control to ensure equal loading of 
proteins. Each well was adjusted according to the corresponding β-actin control. The columns in the graph represent 
the density ratio for each nAChR subtype. 
 
3.1.3 Immunocytochemistry 
To further demonstrate the presence and localisation of the nAChR subtypes on cancer cells, 
immunocytochemistry was performed on untreated MDA-MB-231 cells. The immunocytochemistry 
images for non-permeabilised and permeabilised cell samples stained for the nAChR α7 and α9 
subtypes are presented in Figure 6 and Figure 7, respectively. Staining with the α7 nAChR subtype 
antibody in non-permeabilised cell samples showed widespread expression (Figure 6A). Subtype 
expression was clearly displayed on the surface of the cancer cells, with much of the α7 labelling 
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following the numerous cell processes. However, significant unknown staining of the α7 antibody 
was seen in the extracellular environment. A high cluster of staining was also observed around the 
nucleus of the carcinoma cells, predominately in the permeabilised MDA-MB-231 samples (Figure 
6B). 
A diverse pattern of receptor subtype expression was observed for MDA-MB-231 cells 
treated with the α9 antibody. Non-permeabilised cell samples showed specific staining of receptor 
subtypes that mimic the flow of the cellular cytoskeleton (Figure 7A). A similar trend was seen in 
the permeabilised cell samples (Figure 7B). Furthermore, the α9 antibody of permeabilised samples 
stained the region of mitotic spindles within the nucleus of replicating cells. Slight extracellular and 
high-density staining was seen with the α9 antibody; however, not as predominately as compared to 





Figure 6: Immunocytochemistry images of non-permeabilised (A) and permeabilised (B) MDA-MB-231 cells showing 
α7 nAChR subtype expression. Cells were treated with the primary α7 nAChR antibody with a fluorescent Alexa Fluor® 
488 secondary antibody (green) and the Hoechst nuclear stain (blue). The treated cells were visualised using an upright 
Nikon Eclipse Ni-E Motorised microscope with a 100x objective lense. DAPI and FITC images were overlayed using 







Figure 7: Immunocytochemistry images of non-permeabilised (A) and permeabilised (B) MDA-MB-231 cells showing 
α9 nAChR subtype expression. Cells were treated with the primary α9 nAChR antibody with a fluorescent Alexa Fluor® 
488 secondary antibody (green) and the Hoechst nuclear stain (blue). The treated cells were visualised using an upright 
Nikon Eclipse Ni-E Motorised microscope with a 100x objective lense. DAPI and FITC images were overlayed using 






Currently, there is only limited information in the literature describing the effects of nAChR 
antagonists on cancer cell development. The present studies examined the effects of both 
established and novel nAChR modulators on cell viability of a variety of carcinoma cell types using 
a cell viability assay. In addition, the study aimed to determine the key nAChR subtypes involved in 
mediating these responses. It was predicted that the selective nAChR antagonists, such as the 
marine toxins, would display the most potent effects on viability of the carcinoma cell types; while 
the α7 and α9 receptor subtypes were anticipated to be the most prominently expressed of the 
nAChR subtypes.  
Both ACh and NIC were used as positive controls to investigate whether the characteristic 
increase in cell viability and expression of nAChRs could be replicated due to their strong agonistic 
effects at nAChRs. Viability assay results demonstrated an ~20-30% increase in cell viability of 
HT29 cells over 72 hours following treatment with 10 μM ACh or NIC. However, the change in 
viability following treatment with ACh or NIC was not reflected in the remaining carcinoma cell 
types investigated. Previous studies have demonstrated the ability of NIC to increase cancer cell 
proliferation, with the most significant effects seen in lung cancer cell lines (not tested in the 
present study) (Dasgupta et al., 2009; Tsurutani et al., 2005). The current literature has shown that 
changes in lung cancer cell proliferation and cellular activity could be observed within 5 hours of 
NIC treatment. However, it is possible that the extensive nAChR expression on lung cancer cells 
differs from the expression patterns of the carcinoma cell types tested in this research. This theory is 
supported by the Western Blot results, where lower levels of the key nAChR subtypes linked to cell 
proliferation, α7 and α9, were shown compared to the highly responsive HT29 cells. The 10 μM 
concentration of ACh and NIC was continued due to the possibility of the compounds having an 
underlying effect on nAChR expression or changes in intracellular calcium concentration ([Ca2+]), 
based on previous literature findings. 
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Similar effects on HT29 cell proliferation have been previously shown with NIC promoting 
cell proliferation, with a dose-dependent increase in DNA synthesis and adrenaline production 
(Wong et al., 2007). The study suggested a link between the expression of the α7-nAChR subtype 
and NIC-induced proliferation, with selective α7-nAChR blockage reversing the stimulatory effects 
on cell proliferation. The present study is consistent with these findings, in that a significant 
increase in HT29 cell proliferation was observed following nAChR stimulation that correlated with 
a higher level of α7 expression in HT29 cells, compared to all other cell lines tested.  
 Significant decreases in cell viability were observed following MECA, PnTX, 5-HT and 
ADI treatment. PnTX was the most potent of the compounds tested, causing as much as a ~70% 
decrease in cell viability at a concentration 200-fold lower than that of the other nAChR 
antagonists, with the most prominent effects seen in HT29 cells. PnTX A and G have been 
previously shown to potently antagonise human α7 and α4β2 nAChRs (Araoz et al., 2011). Human 
nAChR-expressing Xenopus oocytes showed significant blocking of α7 nAChR with nM 
concentrations of PnTX A that was not reversible after 10-15 minutes washout. While PnTX A also 
blocked the human α4β2 nAChR at higher concentrations, indicating that the toxin may be more 
selective for the α7 subtype. PnTX G shows similar effects in oocyte-expressing nAChRs, but at 
significantly higher concentrations than PnTX A (Araoz et al., 2011). The present results suggest 
that PnTX is inducing carcinoma cell cytotoxicity through similar mechanisms, with both α7 and α4 
nAChR subtypes being widely expressed amongst the cell lines tested. In addition, the 
responsiveness of the cell lines was also correlated to the expression of the receptor subtypes, with 
the highly expressive HT29 cells being the most sensitive to PnTX treatment. Conversely, the U87 
cells had low nAChR expression and were the least sensitive to PnTX treatment.  
 The results of the non-selective nAChR antagonist, MECA, showed similar levels of 
viability decrease compared to PnTX, but at a 200-fold higher concentration. It is reported in the 
literature that MECA inhibits various nAChRs, including α4β2, α3β2, α3β4 and α7, with the least 
potent effects observed at α7 nAChRs (Papke et al., 2001). Due to this relatively low selectivity for 
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the α7 nAChR, the present study suggests that higher concentrations of MECA are required to 
induce α7-related cytotoxicity, compared to the selective α7-antagonist, PnTX.  A potent decrease 
in cell viability was also observed following ADI treatment of the various carcinoma cell types, 
similar to that seen for MECA. ADI acts via blocking heteromeric nAChR containing α3 or α4 
subunits (eg α3β4, α4β2, α4β4) suggesting the cytotoxic effects may be mediated through the α4 
expression on carcinoma cell types (Gentry et al., 2001). The comparative effects of MECA and 
ADI, compared to PnTX, demonstrate the importance of both the α7 and α4 nAChR subtypes in 
inducing cell cytotoxicity. However, the high concentrations of both MECA and ADI required to 
induce a decrease in carcinoma cell viability question the mechanism behind the observed results. 
Both MECA and ADI exhibit IC50 values <15 μM at nAChRs.  The use of concentrations well 
above the IC50 for both compounds in the present study may reduce the selectivity of these 
compounds at the specific nAChRs, potentially inducing changes in cell viability through alternate 
mechanisms. Additional studies using siRNA knockdown of critical nAChRs would be required to 
confirm the mechanism behind the changes in carcinoma cell viability as a result of MECA and 
ADI treatment.  
 Significant effects on cell viability were also observed following treatment with 5-HT, with 
a significant decrease in cell viability across all cell lines tested at 72 hours post treatment. The 
effects were consistent with those previously observed with 5-HT reuptake inhibitors (Gil-Ad et al., 
2008; Schuller, 2009). It is possible that these effects of 5-HT are mediated through the expression 
of chimeric nACh–5-HT receptors that are expressed within the nervous system. Over-activation of 
5-HT receptors has been shown to induce a significant downregulation of 5-HT receptors on the cell 
surface of neurons (Gray et al., 2001). The treatment of 5-HT in the present study may induce 
similar effects on chimeric nACh–5-HT receptors, reducing the expression of functional nACh–5-
HT receptors on the cell surface through receptor internalisation. The decrease in the nAChR 
component may cause a fatal decrease in [Ca2+] levels, relating to the observed cancer cell 
cytotoxicity at high doses of 5-HT. This theory would explain why previous literature has shown 
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the ability of 5-HT reuptake inhibitors to eliminate the effects of nicotine and nicotine-derived 
nitrosamines. 
 Interestingly, both MLA and GYM treatment had little effect on cancer cell viability with 
only MDA-MB-231 and U373 cells showing a significant decrease in cell viability at 72 hours. 
MLA exhibits a very high selectivity towards homomeric α7 nAChR, with the ability to bind to one 
of five identical binding sites present on the α7 nAChR with an IC50 in the picomolar range (Palma 
et al., 1996). MLA is thought to share the same binding sites to the α7 AChRs as the endogenous 
agonist ACh, with the binding of a single MLA molecule to the receptor sufficient to prevent its 
channel opening. However, unlike many antagonistic toxins that irreversibly bind the nAChR, 
recovery of nAChR function is observed following MLA treatment (Palma et al., 1996). These 
findings suggest that MLA may only have a significant effect on cellular function in the presence of 
an agonist, such as ACh, compared to treatment with the agonist alone due to the competitive 
binding nature of the compound. This idea was further investigated in Chapter 3 where [Ca2+] levels 
of MDA-MB-231 cells were measured following MLA treatment. In addition, the reversible 
binding of MLA may explain the lack of cytotoxicity observed following high concentrations of 
MLA treatment, with 72 hours providing sufficient time for the cancer cells to recover and 
proliferate.  
 The treatment of cancer cells with GYM was predicted to induce similar effects on cell 
viability as PnTX due to their similarity in chemical structure and nAChR selectivity. GYM has 
been previously shown to selectively block homomeric α7 nAChRs expressed in Xenopus oocytes 
and heteropentameric α3β2 and α4β2 nAChRs during competition-binding assays (Kharrat et al., 
2008). Despite GYM displaying similar IC50 values of 0.33 and 15.5 nM at human α7 and α4β2 
nAChRs, respectively, compared to PnTX, the effects on in vitro cell viability have been opposing 
(Shin et al., 2005). Treatment of Neuro2a cells incubated with 10 μM GYM for 24 hours showed no 
significant change in cell viability by MTT assay, while GYM at concentrations 10-fold higher have 
also been relatively non-toxic on primary cultures of mouse cortical neurons (Alonso et al., 2011; 
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Dragunow et al., 2005). The result of the present study show similar effects on cell viability, with 
no significant changes in cell viability, with the exception of MDA-MB-231 cells, following 
treatment with 10 μM GYM for 72 hours. The difference in effects between GYM and PnTX may 
be due to the reversible binding nature of GYM, showing full recovery within 30 minutes of 
washout in hemidiaphragm preparation, compared to the slow and incomplete recovery of tissue 
following PnTX treatment (Hellyer, 2014; Hellyer et al., 2011).  
 The effects of the various compounds of cancer cell viability have been demonstrated. As 
noted in Section 2.1.3 (MTT Assay), the assay method measures viable cell activity through the 
enzymatic reduction of MTT. However, the method is unable to distinguish between a decrease in 
cell activity due to cytotoxicity or an inhibition of cell proliferation. Therefore, the data from the 
cell viability assay cannot clarify whether nAChR antagonism is having a cytotoxic effect on the 
cells, or preventing the cells from replicating. Microscopic imaging of the treated cells indicate that 
some compounds, such as PnTX, may be preventing cell proliferation due to a lack of cell death 
observed. However, additional tests, such as flow cytometry analysis of the treated cells discussed 
in the following sections, was required to further investigate the effects of these compounds on cell 
viability. 
To further investigate the presence and localisation of the α7 and α9 nAChR subunits on 
cancer cells, immunocytochemistry (ICC) was performed on untreated MDA-MB-231 breast 
carcinoma cells. The α9 nAChR is an integral subunit in the development of breast cancer due to its 
upregulation following activation of the estrogen receptor, having implications in cancer growth 
and metastasis (Lee et al., 2011). Furthermore, the importance of the α7 nAChR subunit has been 
linked to several aspects of cancer development. ICC images from non-permeabilised cells treated 
with the α7 antibody displayed significant staining on the surface of the cells, including the 
numerous cell processes extending from the cell body. Significant levels of expression were also 
observed with the α9 antibody, with a pattern that more closely resembles the cell cytoskeleton, 
rather than small clusters of receptors on the cell surface. According to current knowledge, this is 
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the first attempt to identify the expression of the α9 nAChR using an ICC method in human breast 
cancer cells, making a comparison of the expression pattern with current literature difficult. Overall, 
the ICC images exhibit the widespread expression of the key nAChR subtypes linked to 
carcinogenesis on the cell surface of human cancer cells, with expression levels that are consistent 
with those seen during the Western blot analysis for MDA-MB-231 cells. However, a lack of 
reproducibility of the experiments due to difficulty with the method and optimisation of the 
antibodies means further experiments would be required to confirm these conclusions.  
The significant amount of non-specific binding of both antibodies within the extracellular 
region and nucleus of the cancer cells questions the specificity of the antibodies to selectively detect 
the α7 and α9 nAChR subunits. It is possible that extracellular staining may be abridged by changes 
to the blocking and washing steps, reducing the non-specific expression and binding of the antibody 
to cell fragments. Alternatively, the observed expression of the antibodies within the nucleus may 
be due to known nuclear binding characteristic of the ER in breast carcinomas and link to α9 
nAChR expression (Lee et al., 2011). 
Having demonstrated an effect with various nAChR modulators on carcinoma cell viability, 
the next step was to explore possible mechanisms of action.  
 
3.2 Investigation of nAChR Antagonist Induced Cell Death 
In the previous chapter it was demonstrated that selective nAChR antagonists induce cell 
death in carcinoma cell lines. To investigate the mechanism(s) of nAChR modulator-induced 
cytotoxicity (Aim II), Western blotting and flow cytometry were used to further characterise the 
treated carcinoma cells. 
3.2.1 Western Blot – α7 nAChR Levels following Treatment 
Western blot analysis was used to investigate the effects of the various nAChR modulators on 
α7 nAChR subtype expression (Figure 8). The α7 nAChR receptor was the main focus of the 
Western blot study due to its widespread expression and involvement in cancer development. 
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Treatment with the nAChR agonists, ACh 10 µM and NIC 10 µM, showed little effect on α7 
expression compared to untreated cells. Of the four cell lines tested, only slight increases in α7 
expression were seen in MDA-MB-231. MDA-MB-231 treatment with various nAChR antagonists, 
including MECA, PnTX, GYM, MLA and ADI, produced a similar increase in α7 expression 
ranging from 1.32 to 1.47-fold compared to untreated cells. No consistent increases in α7 
expression were seen across all other cell lines or treatments. LN-18 cells were the least responsive 
to treatment with nAChR modulators, with α7 expression decreasing following treatment with all 
compounds, with the exception of MECA 1000 µM. 
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Figure 8: Western blot analysis investigating the effects of various nAChR modulating compounds on the expression 
level of the α7 nAChR subtype in MDA-MB-231, HT29, PC3 and LN18 cancer cell lines. Cells were either left untreated 
or treated with ACh 10 µM, NIC 10 µM, MECA 1000 µM, PnTX 5 µM, GYM 10 µM, 5-HT 1000 µM, MLA 100 µM and 
ADI 250 µM for 72 hours prior to harvesting and analysis. β-actin protein was used as a loading control to normalise 
loading of proteins. The columns in the graph represent the fold change in density ratio between the treatment group 




3.2.2 Flow Cytometry - Cell Cycle Analysis 
Cell cycle analysis was conducted using the propidium iodide (PI) DNA stain to determine 
the proportion of cells in each stage of the cell cycle. The percentage of cells in the sub-G1 stage of 
the cell cycle was measured using Fluorescent Activated Cell Sorting (FACS) following treatment 
with the various nAChR modulators, as displayed in Figure 9. An increase in sub-G1 percentage 
represents an increase in fractional DNA content, characteristic of apoptotic cells. CDDP was 
chosen as it is known to induce cell apoptosis through mitochondrial depolarisation, 
phosphatidylserine translocation and caspase activation (Cregan et al., 2013). Treatment with ACh 
10 µM, NIC 10 µM and MLA 100 µM had no effect on the percentage of cells in sub-G1. A 
significant (P < 0.001) increase in DNA fragmentation was seen for all other treatments in all cell 
lines compared to untreated controls, with the exception of GYM 10 µM and ADI 250 µM 
treatment of MDA-MB-231 cells (no significant change in DNA fragmentation).  
MECA 1000 µM and 5-HT 1000 µM produced consistent increases in the percentage of cells 
in sub-G1 compared to untreated cells, at similar levels to the positive control (CDDP 20 µM) 
(Figure 9). The significant change in cells in sub-G1 was consistent with the cell viability results for 
each treatment, where significant decreases in cell death were seen over the same concentrations 
(Figure 4A and Figure 4D). A significant ~2-fold increase in the sub-G1 cells was also seen 
following PnTX 5 µM treatment of all cell lines (Figure 9). However, despite similar viability 
losses between the treatments (Figure 4B), PnTX sub-G1 levels were substantially lower than those 
seen following MECA (>10-fold) and 5-HT (>12-fold) treatment. Treatment with GYM 10 µM 
produced a significant increase in apoptotic HT29 (Figure 9B) and PC3 (Figure 9C) cells, with 























































































































































































































































































Figure 9: Cell cycle analysis of antagonist treated MDA-MB-231 (A), HT29 (B) and PC3 (C) cell lines. Cells were 
treated with ACh 10 µM, NIC 10 µM, MECA 1000 µM, PnTX 5 µM, GYM 10 μM, 5-HT 1000 µM, ADI 250 µM, and 
MLA 100 µM for 72 hours prior to ethanol-fixation, propidium iodide staining and fluorescence-activated cell sorting 
(FACS). Additionally, untreated cells were used as a negative control, while CDDP 20 µM treatment was used as a 
positive control. The mean percentage of cells in the sub-G1 stage of the cell cycle has been calculated for each sample. 
Values are displayed as the mean percent of cells in sub-G1, with error bars representing SEM (n = 5). A one-way 
ANOVA with a Dunnett’s post-hoc test was used to determine significance compared to the untreated control (*** P < 
0.001). 
 
In addition to the Sub-G1 apoptotic group, the percentage of cells within each stage of the 
cell cycle, including, G0/G1, S and G2/M, were determined to examine whether nAChR treatment 
caused mitotic inhibition during any stage of cell division. The various stages of the cell cycle were 
elucidated from the interactions of DNA with the fluorescent PI stain. Cells preparing for cell 
division will contain increasing amounts of DNA; therefore, displaying a comparative increase in PI 
fluorescence (Wlodkowic et al., 2011). 
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No consistent change in the percentage of cells within each cell cycle region was seen 
following GYM 10 μM and MLA 100 μM treatment of MDA-MB-231 (Figure 10), HT29 (Figure 
11) and PC3 (Figure 12) cells. MECA 1000 μM treatment produced a significant decrease in the 
percentage of cells in G0/G1, S and G2/M of the cell cycle, compared to untreated cells. The 
observed decrease correlated with a large increase in sub-G1 cells following MECA treatment. 
Similar effects were observed following 5-HT treatment of MDA-MB-231, HT29 and PC3 cells. 
Changes to the number of cells within each stage of the cell cycle were variable following 
PnTX 5 μm and ADI 250 μm treatment. PnTX treatment caused a significant increase (P < 0.001) in 
MDA-MB-231 (Figure 10B) and PC3 (Figure 12B) cells in the G0/G1 region of the cell cycle, 
suggesting PnTX may induce cell growth inhibition through G0/G1 arrest. This effect was not 
observed in HT29 cells following PnTX treatment. Interestingly, PnTX treatment of HT29 cells did 
produce a significant increase in cells within the S and G2/M regions, compared to untreated cells 
(P < 0.001) (Figure 11B). Comparable results were seen following ADI 250 μm treatment of MDA-





























































































































































































































































































Figure 10: Cell cycle analysis of treated MDA-MB-231 cells measured via flow cytometry. Cells were treated with 
MECA 1000 µM (A), PnTX 5 µM (B), GYM 10 μM (C), 5-HT 1000 µM (D), ADI 250 µM (E), and MLA 100 µM (F) for 
72 hours prior to ethanol-fixation, propidium iodide staining and fluorescence-activated cell sorting. Untreated cells 
were used as a negative control. The mean percentage of cells in each stage of the cell cycle has been calculated for 
each sample. The error bars represent SEM (n = 5). A two-way ANOVA with a Bonferroni post-hoc test was used to 
































































































































































































































































































Figure 11: Cell cycle analysis of treated HT29 cells measured via flow cytometry. Cells were treated with MECA 1000 
µM (A), PnTX 5 µM (B), GYM 10 μM (C), 5-HT 1000 µM (D), ADI 250 µM (E), and MLA 100 µM (F) for 72 hours 
prior to ethanol-fixation, propidium iodide staining and fluorescence-activated cell sorting. Untreated cells were used 
as a negative control. The mean percentage of cells in each stage of the cell cycle has been calculated for each sample. 
The error bars represent SEM (n = 5). A two-way ANOVA with a Bonferroni post-hoc test was used to determine 






























































































































































































































































































Figure 12: Cell cycle analysis of treated PC3 cells measured via flow cytometry. Cells were treated with MECA 1000 
µM (A), PnTX 5 µM (B), GYM 10 μM (C), 5-HT 1000 µM (D), ADI 250 µM (E), and MLA 100 µM (F) for 72 hours 
prior to ethanol-fixation, propidium iodide staining and fluorescence-activated cell sorting. Untreated cells were used 
as a negative control. The mean percentage of cells in each stage of the cell cycle has been calculated for each sample. 
The error bars represent SEM (n = 5). A two-way ANOVA with a Bonferroni post-hoc test was used to determine 
significance compared to the untreated control (* P < 0.05, ** P < 0.01, *** P < 0.001). 
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3.2.3 Flow Cytometry - TMRE 
To further investigate early apoptosis of the various cancer cell lines using flow cytometry, 
the TMRE stain was used on cell samples treated with the most cytotoxic nAChR modulating 
compounds (MECA, PnTX, 5-HT and ADI). TMRE is a positively-charged dye that accumulates in 
active mitochondria due to the negatively charged nature of the mitochondrial membrane potential. 
Therefore, a left shift in the FL2-H fluorescence peak compared to untreated cells indicates an 
inability of the mitochondria to sequester the TMRE due to depolarisation of the mitochondrial 
membrane potential, as observed during cell apoptosis.. 
The TMRE histograms for the individual treatments and cell types have been presented in 
Figure 13A, with percentage of cells with low TMRE intensity graphed (Figure 13B). High levels 
of TMRE staining were shown in the untreated cell samples, with consistent shifts in FL2-H peaks 
following treatment with the CDDP 20 µM positive control (indicative of a loss in mitochondrial 
membrane permeability during early apoptosis). Results following ADI 1000 µM for 72 hours 
showed a complete shift in FL2-H, with diminutive staining of active mitochondria. MECA 1000 
µM and 5-HT 1000 µM treatment showed shifts in FL2-H peak comparable to the CDDP positive 
control. PnTX 5 µM induced only a minor shift in FL2-H while still showing considerable TMRE 
staining of active mitochondria. The results seen following PnTX 5 µM treatment were 
considerably less pronounced compared to all other treatments (Figure 13B), producing only a small 
but significant change from the untreated control, despite the similar effects on cell viability loss 
(Figure 4B).  
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Figure 13: Evaluation of the mitochondrial transmembrane potential of MDA-MB-231, HT29 and PC3 cell lines 
measured via flow cytometry to identify the early stages of cell apoptosis. Cells were treated with MECA 1000 µM, 
PnTX 5 µM, 5-HT 1000 µM or ADI 1000 µM for 72 hours prior to TMRE staining and fluorescence-activated cell 
sorting. Additionally, untreated cells were used as a negative control, while CDDP 20 µM treatment was used as a 
positive control. Dot-plots represent FL2-H fluorescence versus cell number, where a shift in peak from left to right 
signifies a collapse in mitochondrial transmembrane potential (A). The relative percentage of cells with low TMRE 
intensity was graphed (B) with the error bars representing the mean ± SEM (n = 3). A one-way ANOVA with a 




3.2.4 Flow Cytometry - Annexin V/PI 
The Annexin V/PI double staining was assessed by flow cytometry to distinguish between 
early apoptotic and necrotic cell death following the treatment of cancer cells with the same nAChR 
modulating compounds used in TMRE studies. Quadrants were determined based on the Annexin V 
(FL1-H) and PI (FL2-H) staining of untreated cells, and kept constant across all treatments. Cells 
within the left-bottom quadrant represent viable cells. A shift of cells into the right-bottom quadrant 
represents phosphatidylserine translocation to the cell surface through an increase in Annexin V 
staining, indicative of early apoptosis. As cells enter late apoptosis, PI may penetrate the 
compromised cell wall and stain the DNA, as indicated by the presence of cells within the right-top 
quadrant. Similarity, secondary necrotic cells demonstrate a similar increase in both PI and Annexin 
V staining as the cell wall deteriorates during necrosis; while an increase in PI staining with no 
change in Annexin V staining has not been clearly characterised in the literature (Wlodkowic et al., 
2011).  
The results of Annexin V/PI double staining of treated MDA-MB-231 cells have been 
presented in Figure 14. Low basal levels of apoptotic and necrotic cells were seen in the untreated 
control cells (6.55%). Considerable increases in Annexin+/PI- (early apoptosis) and Annexin+/PI+ 
(late apoptosis) stained cells were seen across all treatments, including the CDDP positive control. 
ADI 1000 µM and MECA 1000 µM produced the greatest increase in apoptotic cells, with 80.49% 
and 71.53% of cells, respectively, within the positively stained Annexin V region. Lower levels of 
Annexin+/PI- and Annexin+/PI+ stained cells were seen following PnTX 5 µM (41.85%) and 5-HT 
1000 µM (31.13%) treatment, relative to ADI and MECA treatment. Nevertheless, the results 
obtained following PnTX and 5-HT treatment were still well above the 7.57% seen within the 
untreated sample. The same substantial increases seen in Annexin+/PI- and Annexin+/PI+ stained 
cells for all treatments compared to untreated cells was not seen within the Annexin-/PI+ quadrant. 
A maximum 3-fold increase in Annexin-/PI+ cells following MECA 1000 µM treatment was 
observed compared to untreated cells.  
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The percentage of MDA-MB-231 cells within the Annexin+/PI- bottom right quadrant has 
been graphed in Figure 14G. All treatments, including the CDDP positive control, caused a 
significant increase in Annexin+/PI- cells compared to control (P < 0.001). The significant increase 
in Annexin+/PI- cells following treatment with MECA, PnTX, 5-HT and ADI indicates an increase 
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Figure 14: Flow cytometric detection of apoptotic and necrotic cells by fluorescence-activated cell sorting of propidium 
iodide and Annexin V labelled MDA-MB-231 cells. Cells were treated with MECA 1000 µM (B), PnTX 5 µM (C), 5-HT 
1000 µM (D) or ADI 1000 µM (E) for 72 hours prior to staining and analysis. Untreated cells (A) were used as a 
negative control, while CDDP 20 µM (F) treatment was used as a positive control. Dot-plots represent individual 
stained cells. The left-bottom quadrant represents viable cells (Annexin-/PI-). The right-bottom quadrant represents 
early apoptotic cells (Annexin+/PI-). Late apoptotic or secondary necrotic cells are represented by the right-top 
quadrant (Annexin+/PI+). Early apoptotic (Annexin+/PI-) cells were graphed (G) with the error bars representing the 
mean ± SEM (n = 3). A one-way ANOVA with a Dunnett’s post-hoc test was used to determine significance compared 




























Comparable results were seen within the HT29 treated cell samples, as shown in Figure 15, 
with considerable increases in apoptotic and necrotic cells observed following the various 
treatments, compared to the low basal levels of the control. ADI 1000 µM and MECA 1000 µM 
treatment again produced the greatest increase in apoptotic cells, with 97.59% and 62.96% of cells 
within the Annexin+ region for the respective treatments. Lower levels of apoptotic cells were seen 
following PnTX 5 µM and 5-HT 1000 µM treatment. PnTX treatment produced a slight increase in 
Annexin+ cells (24.96%) compared to the 7.81% for untreated cells; while 5-HT was comparable to 
PnTX treatment with 28.74% of cells within the Annexin+ region.  Significant increases in Annexin-
/PI+ stained cells were seen following MECA 1000 µM, 5-HT 1000 µM and CDDP 20 µM 
treatment, with values of 22.57%, 19.93% and 14.26%, respectively, compared to untreated cells 
(3.90%). Such large increases in Annexin-/PI+ stained cells was unique to HT29 cells, and not seen 
in the other cell lines tested. 
Significant increases in early apoptotic Annexin+/PI- cells were seen following treatment with 
MECA (P < 0.001), PnTX (P < 0.001) and ADI (P < 0.05), compared to untreated cells (Figure 
15G). No significant change in Annexin+/PI- cells was observed following 5-HT treatment, 
compared to control. However, a large increase in secondary necrotic/late apoptotic cells following 
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Figure 15: Flow cytometric detection of apoptotic and necrotic cells by fluorescence-activated cell sorting of propidium 
iodide and Annexin V labelled HT29 cells. Cells were treated with MECA 1000 µM (B), PnTX 5 µM (C), 5-HT 1000 
µM (D) or ADI 1000 µM (E) for 72 hours prior to staining and analysis. Untreated cells (A) were used as a negative 
control, while CDDP 20 µM (F) treatment was used as a positive control. Dot-plots represent individual stained cells. 
The left-bottom quadrant represents viable cells (Annexin-/PI-). The right-bottom quadrant represents early apoptotic 
cells (Annexin+/PI-). Late apoptotic or secondary necrotic cells are represented by the right-top quadrant 
(Annexin+/PI+). Early apoptotic (Annexin+/PI-) cells were graphed (G) with the error bars representing the mean ± 
SEM (n = 3). A one-way ANOVA with a Dunnett’s post-hoc test was used to determine significance compared to the 




























The cell death profiles of PC3 cells displayed a high level of apoptotic cells within the 
untreated control, with 54.34% of cells within the Annexin+ region due to excessive confluency of 
the cells at 72 hours (Figure 16). Increases in apoptotic cells were still however seen following 
treatment with the various compounds. ADI 1000 µM and 5-HT 1000 µM produced the greatest cell 
death, with respective Annexin+ values of 98.37% and 92.62 %. PnTX 5 µM treatment displayed 
apoptotic results similar to the CDDP 20 µM control, with 85.57% of cells within the Annexin+ 
region. MECA 1000 µM treatment produced only a minor increase in Annexin+ apoptotic cells, with 
a value of 62.83%, compared to untreated cells. Similar levels of Annexin-/PI+ stained cells were 
observed across all treatments, contrary to results seen for the other cell lines tested. 
Treatment with MECA and PnTX were the only two treatments to produce significant 
increases in early apoptotic cells, compared to untreated cells (Figure 16G). However, further 
analysis of the dot-plots show all treatments produced a consistent reduction in viable cells, with 
large populations of cells within the secondary necrotic/late apoptotic region.  
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Figure 16: Flow cytometric detection of apoptotic and necrotic cells by fluorescence-activated cell sorting of propidium 
iodide and Annexin V labelled PC3 cells. Cells were treated with MECA 1000 µM (B), PnTX 5 µM (C), 5-HT 1000 µM 
(D) or ADI 1000 µM (E) for 72 hours prior to staining and analysis. Untreated cells (A) were used as a negative 
control, while CDDP 20 µM (F) treatment was used as a positive control. Dot-plots represent individual stained cells. 
The left-bottom quadrant represents viable cells (Annexin-/PI-). The right-bottom quadrant represents early apoptotic 
cells (Annexin+/PI-). Late apoptotic or secondary necrotic cells are represented by the right-top quadrant 
(Annexin+/PI+). Early apoptotic (Annexin+/PI-) cells were graphed (G) with the error bars representing the mean ± 
SEM (n = 3). A one-way ANOVA with a Dunnett’s post-hoc test was used to determine significance compared to the 




























Western blot analyses and flow cytometry studies were used to examine the role of the most 
potent nAChR modulators in inducing carcinoma cell death. It was initially hypothesised that the 
selective nAChR antagonists would display the greatest cytotoxic effects on the various carcinoma 
cell lines. The cell viability results previously discussed in Section 3.1 Effects of nAChR 
Antagonists on Cell Viability demonstrated that the selective α7/α4β2 nAChR antagonist, PnTX, 
displayed the most potent cytotoxic effects, while other selective antagonists, such as GYM and 
MLA, were less toxic. The results of the cell viability studies were predicted to translate to the flow 
cytometry results. In other words, the compounds with the greatest cytotoxic effects were expected 
to have a significant impact on nAChR subtype expression, while inducing the greatest level of cell 
apoptosis.  
The Western blot analysis focused on the α7 nAChR subtype because of its widespread 
expression, as observed in the previous studies. MDA-MB-231 cells showed a small increase in α7 
expression following treatment with the various nAChR modulators, with the exception of 5-HT 
treatment, while varying results were observed for all other cell lines. The literature reports that the 
biological functions of the α7 nAChRs are increased following NIC exposure (Schuller, 2009). 
Plummer and colleagues demonstrated the ability of the α7 nAChR to be significantly upregulated 
in NCL-H69 human lung carcinoma cells following treatment with 100 ρM NNK. Changes in the 
expression of the α7 nAChR subtype could be seen as early as 60 minutes following treatment; 
however, the increase in expression was not observed at 24 hours post treatment (Plummer 3rd et 
al., 2005). The present results following ACh or NIC treatment demonstrate little change in α7 
expression across the cell types tested. A lack of a consistent change in α7 expression may be 
attributed to the 72 hour treatment time, with changes in expression potentially occuring earlier in 
the treatment period, as suggested by the literature. Similarly, no consistent changes in α7 
expression were observed following treatment with the various nAChR antagonists. It was predicted 
that the nAChR antagonists would produce a reduction in the α7 nAChR expression; however, the 
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observed results showed inconsistent changes between cell lines with no clear trends in α7 
expression following treatment.  
Tests to investigate the mechanism of cell death for the most cytotoxic nAChR modulators 
were conducted on the MDA-MB-231, HT29 and PC3 cell lines. Flow cytometry cell cycle analysis 
of treated cells following PI staining showed a significant increase in fractional DNA content 
following MECA, PnTX, GYM (excluding MDA-MB-231 cells), 5-HT and ADI treatment, 
compared to untreated cells. Interestingly, PnTX treatment induced small, but significant increases 
in the percentage of cells in the sub-G1 fraction, indicating lower levels of apoptosis compared to 
the other treatments investigated. An analysis of the complete cell cycle of MDA-MB-231 and PC3 
cells indicated that PnTX treatment delayed the progression of cells from the G0/G1 phase into the 
S phase. Similar results were observed following TMRE staining, with all treatments investigated 
inducing significant mitochondrial membrane permeability, characteristic of early apoptosis.  
Annexin V/PI double stain demonstrated significant increases in the presence of early apoptotic 
cells and late apoptotic/necrotic cells following a 72 hour treatment period. PnTX showed a 
consistently high level of early apoptotic cells compared to the other treatments tested, however 
displayed lower levels of late apoptotic/necrotic cells, indicating a delayed onset of cell apoptosis 
compared to the other nAChR antagonists.  
The PnTX induced cell-cycle arrest in the G0/G1 phase may result from changes in [Ca2+] 
through antagonism of α7 and α4β2 nAChRs. Transient rises in [Ca2+] are integral in the process of 
cell division. Rises in [Ca2+], both from intracellular pools and the extracellular environment, occur 
during the early stages of the cell cycle G1 phase. Although cell division requires a vast array of 
physiological responses, Ca2+ acts as a ubiquitous second messenger, initiating many of the 
processes involved during the cell cycle (Kahl et al., 2003). Current literature has demonstrated that 
Ca2+ channel blockers, such as amlodipine, induce G1 phase accumulation by alleviating Ca2+ entry 
into the cell. Amlodipine (30 μM) treatment of A431 human epidermoid carcinoma cells 
demonstrated an ~20% increase in cells within the G0-G1 phase of the cell cycle after 48 hours of 
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treatment, compared to control cells. The reduction in [Ca2+] significantly decreased the expression 
of cyclin D1 and CDK4, specific proteins involved in cell progression through the G1 phase 
(Yoshida et al., 2007). The present results suggest a possible link between PnTX treatment and 
reductions in [Ca2+], resulting in G0/G1 arrest and an inhibition of cell proliferation. Changes in 
[Ca2+] would explain why relatively lower levels of sub-G1 cells and TMRE staining were observed 
following PnTX treatment, despite possessing similar reductions in cell viability compared to other 
treatments investigated. To support this theory, studies looking at the changes in [Ca2+] following 
PnTX treatment were undertaken, as discussed in the next chapter. 
The majority of treatments investigated induced significant levels of apoptosis in the treated 
cells following 72 hours of treatment, demonstrating increases in fragmented DNA, mitochondrial 
membrane permeability and phosphatidylserine translocation, indicative of early apoptosis. The 
present results are consistent with those previously seen for nAChR antagonists. APS8, a non-
competitive and selective α7 nAChR antagonist, has been investigated due to its ability to inhibit 
NSCLC cells growth and activate apoptotic pathways. APS8 treatment of A549 and SKMES-1 cells 
caused significant mitochondrial depolarisation, leading to the release and activation of several 
apoptotic factors involved in the intrinsic pathway (Zovko et al., 2013). Increased expression of 
cytochrome C and SMAC, which are released following mitochondrial permeabilisation, were 
observed following APS8 exposure, inducing the activation of caspase-9, a common inducer of the 
intrinsic pathway (Zovko et al., 2013). PnTX, the most selective and cytotoxic α7 nAChR 
antagonists investigated, induced similar mitochondrial permeabilisation in MDA-MB-231, HT29 
and PC3 carcinoma cell lines. In addition, significant levels of Annexin+/PI-, indicative of early 
apoptosis, suggest PnTX may induce apoptosis in a similar manner to that seen following APS8 
treatment.  
The cell death profile of PnTX differed from the other nAChR antagonists investigated, 
despite showing similar effects in the earlier cell viability studies. PnTX treated cells displayed a 
lower proportion of cells in the sub-G1 phase, lower TMRE staining and higher levels of early 
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apoptotic cells, during the flow cytometric studies. The changes in the cell cycle of the investigated 
cells suggest a possible mechanism by which PnTX treatment could reduce cancer cell proliferation. 
Alternatively, the shift in TMRE staining suggests possible induction of the intrinsic apoptotic 
pathway, contributing to the early apoptotic effects of PnTX. The following chapter looked at 
investigating the inhibition of various downstream apoptotic messengers to further deduce the 
mechanism behind the cytotoxic effects of PnTX.  
 
3.3 Inhibition of nAChR Antagonist Induced Cell Death 
In the previous studies it was shown that nAChR treatment induces potent apoptotic effects in 
carcinoma cell lines. To investigate this phenomenon further, apoptotic inhibitors were used to 
determine whether inhibiting common apoptotic pathways would reduce the cytotoxic effects of the 
nAChR modulators (Aim III).  
The apoptotic pathway, as detailed in Section 1.2.4 Anti-Apoptotic Effects of nAChRs in 
Cancer Survival, is regulated by several key intermediates. Following activation of the extrinsic 
death receptors, or the intrinsic response to cellular stress, the apoptotic pathway is initiated. One 
key pathway is the activation of the Ca2+-dependent proteases, calpains, in response to excessive 
intracellular Ca2+ levels causing cleavage of the Na+/Ca2+ mitochondrial exchanger leading to 
mitochondrial Ca2+ accumulation. This induces changes in the inner mitochondrial membrane 
potential, which stimulates the opening of the mitochondrial permeability transition pore (Elmore, 
2007; Smith et al., 2012). Cytochrome C and small mitochondria-derived activator of caspases 
proteins are released through the pore, activating several downstream mediators, such as cysteine-
dependent aspartic proteases (also known as caspases). The downstream activation of caspase-3 
stimulates the final stages of apoptosis, inducing cytoskeletal reorganisation and disintegration of 
the cell into apoptotic bodies (Elmore, 2007; Smith et al., 2012). Several of these integral steps 
were targeted by the following studies to better understand the cytotoxic effects of nAChR 
modulators on carcinoma cells. 
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3.3.1 Cell Death Inhibitors 
To investigate the possible apoptotic pathways affected by the treatment with the most potent 
nAChR modulator tested, PnTX, various cell death inhibitors were used. MDA-MB-231, HT29, 
PC3 and LN18 cells were treated with cell death inhibitors alone and in combination with PnTX 5 
µM to examine any possible decrease in cell death caused by the PnTX treatment. 
Cyclosporin A (CsA), a potent inhibitor of the opening of the mitochondrial permeability 
transition pore during apoptosis through binding to the cyclophilin D protein, was the first inhibitor 
investigated (Basso et al., 2008) (Figure 17). Other inhibitors tested included ALLN (Figure 18), 
BAPTA (Figure 19) and zVAD (Figure 20). ALLN reversibly blocks the Ca2+-dependent neutral 
cysteine protease calpain I, commonly involved in various cellular processes, including 
proliferation, apoptosis and differentiation (Chen et al., 2002). BAPTA, a known Ca2+ chelator, 
inhibits apoptosis through decreasing [Ca2+] levels critical in the activation of apoptotic caspases 
(Zhao et al., 2005). Furthermore, zVAD inhibits the proteolytic activity of apoptotic enzymes 
through irreversibly binding to the catalytic site of caspase proteases (Gamen et al., 2000). 
The combination treatment of CsA + PnTX 5 µM did no improve the viability of any of the 
four cell lines tested, compared to PnTX 5 µM treatment alone (Figure 17). Conversely, CsA 10 
µM + PnTX 5 µM treatment produced a significant (P < 0.01) 38% decrease in cell viability of 
MDA-MB-231, compared to PnTX 5 µM treatment alone (Figure 17A). 
Similar results were seen across other cell death inhibitors tested with decreases in cell 
viability seen for MDA-MB-231 cells following ALLN 5 µM + PnTX 5 µM (P < 0.001), BAPTA 1 
µM + PnTX 5 µM (not significant) and zVAD 30 µM + PnTX 5 µM (P < 0.01), compared to PnTX 
treatment alone. No significant changes in MDA-MB-231 cell viability were seen following CsA, 
BAPTA or zVAD treatment alone, compared to untreated cells, with only ALLN treatment alone 



















































































































































































































































Figure 17: Examination of the effect of the cell death inhibitor Cyclosporin A (CsA) on PnTX induced cytotoxicity in 
MDA-MB-231 (A), HT29 (B), PC3 (C) or LN18 (D) cell lines, following 72 hours of treatment. Cells were treated with 
either PnTX 5 µM, CsA 1 μM or 10 µM, or a combination of the two following a 24 hour seeding period. Untreated 
cells were used as a negative control, while DMSO was included as a vehicle control. Cell viability was established via 
the MTT assay. Values are displayed as the mean viability (as a percentage) of the viability of control cells, with error 
bars representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was used to determine significance 





































































































































































































































































Figure 18: Examination of the effect of the cell death inhibitor ALLN on PnTX induced cytotoxicity in MDA-MB-231 
(A), HT29 (B), PC3 (C) or LN18 (D) cell lines, following 72 hours of treatment. Cells were treated with either PnTX 5 
µM, ALLN 1 μM or 5 µM, or a combination of the two following a 24 hour seeding period. Untreated cells were used as 
a negative control, while DMSO was included as a vehicle control. Cell viability was then established via the MTT 
assay. Values are displayed as the mean viability (as a percentage) of the viability of control cells, with error bars 
representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was used to determine significance 
between treatment groups. * represents P < 0.05 while *** represents P < 0.001 between the PnTX and the ALLN + 






































































































































































































































































Figure 19: Examination of the effect of the cell death inhibitor BAPTA on PnTX induced cytotoxicity in MDA-MB-231 
(A), HT29 (B), PC3 (C) or LN18 (D) cell lines, following 72 hours of treatment. Cells were treated with either PnTX 5 
µM, BAPTA 1 μM or 5 µM, or a combination of the two following a 24 hour seeding period. Untreated cells were used 
as a negative control, while DMSO was included as a vehicle control. Cell viability was then established via the MTT 
assay. Values are displayed as the mean viability (as a percentage) of the viability of control cells, with error bars 
representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was used to determine significance 



























































































































































































































































































































Figure 20: Examination of the effect of the cell death inhibitor zVAD on PnTX induced cytotoxicity in MDA-MB-231 
(A), HT29 (B), PC3 (C) or LN18 (D) cell lines, following 72 hours of treatment. Cells were treated with either PnTX 5 
µM, zVAD 10, 20 or 30 µM, or a combination of the two following a 24 hour seeding period. Untreated cells were used 
as a negative control, DMSO was included as a vehicle control, while CDDP and CDDP + zVAD was used as a 
positive control. Cell viability was then established via the MTT assay. Values are displayed as the mean viability (as a 
percentage) of the viability of control cells, with error bars representing SEM (n = 3). A one-way ANOVA with a 
Bonferroni post-hoc test was used to determine significance between treatment groups. ** represents P < 0.01 between 
the PnTX and the zVAD + PnTX treatment groups. 
 
3.3.2 Intracellular Calcium 
Intracellular calcium ([Ca2+]) is involved in various cell signalling pathways, including the 
cell apoptotic pathway. Based on the early results linking nAChR modulation and Ca2+ influx 
within a cell (refer to the discussion in Section 3.2 Investigation of nAChR Antagonist Induced Cell 
Death), the [Ca2+] levels of MDA-MB-231, HT29 and PC3 cells were measured following 
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treatment with the various nAChR modulators. The MDA-MB-231, HT29 and PC3 cell lines were 
chosen based on their range of nAChR expression observed during Western blot studies (Figure 5). 
Cells were incubated with 4 µM of the intracellular fluorescent Ca2+ indicator, Fura-2 AM, prior to 
treatment. The [Ca2+] levels were then measured over 360 minutes post treatment, with the 
fluorescence intensity ratio (340 nm/380 nm) displayed in Figure 21. 
Characteristic results were seen following treatment with the known nAChR agonist, ACh 10 
μM, in all cells lines tested. An instant increase in [Ca2+] was seen after 1-2 minutes of ACh 
treatment, compared to untreated control cells. The increase in [Ca2+] was sustained over the first 15 
minutes of recording, eventually returning to baseline after ~60 minutes in both HT29 and PC3 cell 
lines. MDA-MB-231 [Ca2+] levels were less defined following ACh treatment. An initial increase in 
[Ca2+] was seen, however results varied over the 360 minutes of recording with [Ca2+] levels 
remaining above baseline.  
No obvious change in [Ca2+] levels was seen in HT29 and PC3 cell lines following GYM 10 
μM and MLA 100 μM treatment (Figure 21). The level of [Ca2+] for both treatments remained close 
to baseline for the 300 minutes of recordings. Slight variations in [Ca2+] levels of MDA-MB-231 
cells were seen following GYM and MLA treatment. However, [Ca2+] changes were inconsistent 
and not characteristic of the trends seen in the other cell lines tested. The lack of [Ca2+] variation 
following GYM and MLA treatment is consistent with the small changes in cell viability shown for 
both treatments in Figure 4C and Figure 4F. 
Despite the observed decrease in cell viability following treatment with the nAChR 
antagonists MECA and ADI (Figure 4A and Figure 4E), treatment with each compound produced 
an increase in [Ca2+] levels. MECA 1000 μM treatment of HT29 cells produced a noticeable 
increase in [Ca2+], compared to untreated cells. The increase in [Ca2+] was delayed compared to the 
response seen following ACh 10 μM treatment, and returned to baseline after ~60 minutes. A 
similar, however more variable effect was seen in MDA-MB-231 cells, while the increase in [Ca2+] 
levels following MECA treatment could not be repeated in PC3 cells. An obvious increase in [Ca2+] 
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levels was also observed following treatment of MDA-MB-231, HT29 and PC3 cells with ADI 
1000 μM. The increase in [Ca2+] was similar across all three cell lines, lasting for ~15 minutes 
following treatment with ADI.  
Treatment with PnTX 5 μM or 5-HT 1000 μM produced the only consistent decreases in 
[Ca2+] levels among the compounds tested. 5-HT 1000 μM treatment in HT29 and PC3 cells 
produced a noticeable decrease in [Ca2+] levels, which returned to baseline ~120 minutes following 
treatment. A greater and more sustained decrease in [Ca2+] levels was observed following PnTX 5 
μM treatment across all cell lines tested. [Ca2+] levels for cell lines treated with PnTX did not return 
to baseline levels, remaining consistently below the untreated cell group.  
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Figure 21: Ca2+ accumulation through Fura-2 AM detection within MDA-MB-231, HT29 and PC3 cells following ACh 
10 µM, MECA 1000 µM, PnTX 5 µM, GYM 10 µM, 5-HT 1000 µM, ADI 1000 µM  or MLA 100 µM treatment. 
Untreated cells were used as the negative control Cells were allowed to adhere overnight before being treated with 100 
µL/well of 4 µM of the Ca2+ indicator Fura-2 AM. Cells were then treated with one of the corresponding nAChR 
modulators. Fura-2 fluorescence was measured using a fluorescent plate reader at an excitation of 340 nm (λ1) and 
380 nm (λ2), with an emission of 510 nm, over 300 minutes. The fluorescence intensity ratio (R = Fλ1/Fλ2) was 






The effects of various nAChR antagonists on cancer cell viability and their capacity to induce 
cell apoptosis has been discussed in the previous results sections. The current section further 
investigated the mechanism of nAChR-induced cancer cell death. PnTX was chosen as the lead 
compound based on its high affinity to antagonise nAChRs and interesting cytotoxic profile 
compared to the other antagonists investigated.  Various inhibitors of common apoptotic effectors 
were employed in an attempt to reduce the cytotoxic effects of PnTX and further deduce the 
mechanism of cell death. The results showed no significant inhibition of cancer cell apoptosis 
following co-treatment of PnTX with CsA, ALLN, BAPTA and zVAD. Interestingly, the majority 
of apoptotic inhibitors induced a further decrease in cell viability when combine with PnTX, while 
having little effect on cell viability alone.  
The flow cytometry results have suggested an increase in mitochondrial permeabilisation 
following PnTX treatment (refer to Section 3.2.3 Flow Cytometry - TMRE). Changes in 
mitcochondrial permeabilisation occur during activation of the intrinsic apoptotic pathway, 
resulting in release of cytochrome C and a consequent downstream activation of the caspases. CsA 
acts via inhibiting the cyclophilin D protein, preventing opening of the mitochondrial permeability 
transition pore during apoptosis. It was hypothesised that co-treatment with CsA might alleviate 
PnTX induced cytotoxicity through inhibition of the intrinsic apoptotic pathway. Interestingly 
however, CsA treatment with PnTX induced a significant decrease in cell viability, compared to 
PnTX treatment alone in MDA-MB-231 cells, while no change was observed in all other cell lines 
tested. CsA possesses a secondary action through inhibiting phosphatase 2B activity, which may 
explain why a further decrease in cell viability was observed (Marszalec et al., 2005). 
Supplementary studies to investigate the effects of combination treatment with CsA and the broad-
spectrum nAChR inhibitor, MECA, in MDA-MB-231 cells were investigated in the following 
section (Combination T). 
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Similarly, combination treatment of the caspase inhibitor zVAD and PnTX induced a decrease 
in cell viability compared to PnTX treatment alone. Caspases exhibit proteolytic activity, which 
when activated play an almost irreversible role in apoptosis. The activation of effector caspases 
(caspase-3, -6 and -7) facilitates the execution pathway of apoptotic cell death, resulting in 
breakdown of nuclear material and the formation of apoptotic bodies (Elmore, 2007). The present 
results are inconsistent with those seen previously following inhibition of the nAChRs. APS8, a 
known antagonist of α7 nAChRs, induced significant activation of caspase-9 and caspase-3 
following treatment of A549 and SKMES-1 cancer cells (Zovko et al., 2013). Interestingly, NIC has 
also been shown to inhibit the activation of caspase-3 following the treatment of Tca8113 oral 
cancer cells with the known caspase inducer, cisplatin, suggesting a link between nAChR regulation 
and caspase activation (Xu et al., 2007). A lack of restoration of cell viability following caspase 
inhibition in the presence of PnTX suggests PnTX-induced cancer cell cytotoxicity acts via a 
caspase-independent mechanism. The mechanisms mediating caspase-independent apoptosis are not 
well characterised; however, several key cellular events are capable of occurring in the absence of 
caspase activity. Phosphatidylserine externalisation (as demonstrated during flow cytometry studies 
with Annexin V in Section 3.2.4) can occur independently of caspase activation through changes in 
intracellular Ca2+ activity, altering the activity of the key mediators of phosphatidylserine 
externalisation (Cummings et al., 2004). Furthermore, nuclear fragmentation (evident from flow 
cytometry studies with PI in Section 3.2.2) as a result of the activation of DNAses may be 
controlled through non-caspase-related pathways involving Ca2+-dependent DNAse proteins 
(Nitahara et al., 1998). These findings again suggest a role of intracellular Ca2+ alterations in PnTX 
cancer cytotoxicity.  
The detrimental effects of PnTX on MDA-MB-231 and PC3 cell viability increased following 
treatment with the Ca2+ activated calpain inhibitor, ALLN, while having no significant effect on 
HT29 and LN18 viability compared to PnTX treatment alone. Calpains play a role in the execution 
process of apoptosis following activation of the enzymes due to an increase in intracellular Ca2+. 
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Once activated, calpains degrade the membrane, cytoplasmic and nuclear structures during cell 
apoptosis (Momeni, 2011). Changes in mitochondrial permeability and release from intracellular 
stores during apoptosis induce an influx in the intracellular concentration of Ca2+, activating such 
proteins as calpains. The present results suggest that the cytotoxic effects of PnTX may result from 
decreases in intracellular Ca2+ due to the antagonistic effects at α7 and α4β2 nAChRs. This theory is 
further consolidated through the observed effects of BAPTA on PnTX cytotoxicity. The Ca2+ 
chelator, BAPTA, has been utilised in apoptotic studies as a possible inhibitor by reducing the 
intracellular influx in Ca2+ (Zhao et al., 2005). The present results demonstrated that, in some cases, 
BAPTA potentiated the cytotoxic effects of PnTX on cancer cells.   
Due to the results obtained in the apoptosis inhibitory studies, it was hypothesised that the 
cytotoxic effects of the various antagonists, specifically PnTX, were due to changes in [Ca2+] influx 
into the cell, inducing carcinoma cell apoptosis. PnTX treatment demonstrated an obvious and 
sustained decrease in [Ca2+] levels of various carcinoma cells over the 360 minutes of testing 
(Figure 21). Similar effects were not observed following treatment with the other antagonists, with 
only 5-HT treatment producing a transient decrease in [Ca2+].  
PnTX has been identified as a potent antagonist of α7 nAChRs. Recent literature analysing 
the functional capacity of PnTX A and G revealed high affinity binding and potent antagonism for 
the α7 subtype during binding and voltage-clamp electrophysiology studies (Bourne et al., 2015). 
Activation of the α7 nAChRs causes large influxes of intracellular Ca2+, capable of inducing various 
intracellular signalling pathways, without the additional coupling to voltage-gated calcium channels 
(Garduño et al., 2012). This characteristic influx in [Ca2+] is responsible for many of the pro-
carcinogenic effects of nAChRs. The effects of PnTX on [Ca2+] were first identified during studies 
conducted on P388 leukaemia cancer cells (Geiger et al., 2013); however, limited discussions of the 
effects on PnTX on [Ca2+] have since been reported. The present results suggest that PnTX’s ability 
to antagonise the highly Ca2+ permeable α7 nAChRs may be responsible for the observed decrease 
in [Ca2+] levels. These changes in [Ca2+] levels following PnTX treatment could potentially explain 
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the differences in flow cytometric and apoptosis inhibition studies compared to the other treatments 
tested. However, further studies are required to confirm the relationship between PnTX and the 
decrease in [Ca2+] via α7 nAChR antagonism.  
The potential effects of Ca2+ in context of the PnTX induced cell-cycle arrest in the G0/G1 
phase have been discussed in the previous chapter. Cells have been shown to be most susceptible to 
depletions in Ca2+ during the G1 phase of the cell cycle.  Ca2+ is important for the expression of the 
cell cycle genes, FOS, JUN and MYC, which when depleted, reduce cell cycle progression through 
the G1 phase (Kahl et al., 2003). The cytotoxic effects of PnTX may also result from the decreases 
in intracellular Ca2+. A decrease in Ca2+ influx from the extracellular environment can cause the cell 
to release intracellular Ca2+ reserves from the endoplasmic reticulum. In cases such as in the 
presence of PnTX, stress through the chronic depletion of Ca2+ from the endoplasmic reticulum can 
result in cell apoptosis via the intrinsic apoptotic pathway (Delom et al., 2007). The cytotoxic 
effects of PnTX through endoplasmic reticulum stress-induced apoptosis correlates with the 
increases in fragmented DNA and mitochondrial membrane permeability observed during the flow 
cytometry studies. 
In contrast to PnTX, MECA and ADI treatment induced a significant transient increase in 
intracellular Ca2+ in the three carcinoma cell lines tested. Increases in intracellular Ca2+ can also 
initiate cell apoptosis. A significant influx in intracellular Ca2+ can activate cell death effectors, 
such as calpains, which stimulate the cleavage of downstream apoptotic effectors. Initiation of this 
pathway ultimately results in cell apoptosis through mitochondrial permeabilisation and cytochrome 
C release (Roderick et al., 2008). On the basis of this information, the various apoptotic inhibitors 
investigated with PnTX would theoretically have a significant effect on MECA and API induced 
cell death. However, the increase in [Ca2+] due to MECA and ADI treatment was unexpected due to 
the similar antagonistic effects of both compounds on nAChRs. In addition, a similar increase in 
[Ca2+] was shown following treatment with ACh, while ACh has no cytotoxic effects on carcinoma 
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cells. This suggests that the cytotoxic effects of both MECA and ADI may operate through a Ca2+-
independent pathway, contrary to that of PnTX. 
 
3.4 Combination Treatment 
The final studies were conducted to explore the synergistic capacity of the most effective 
nAChR modulators identified in Aims I-III to sensitise cancer cells to common chemotherapy 
agents. It was hypothesised that the nAChR antagonists would enhance the cytotoxic nature of 
chemotherapy agents, at concentrations that were relatively non-cytotoxic when administered alone. 
Cell viability assay, flow cytometry and an isobologram analysis were utilised to identify the most 
effective cytotoxic combination of nAChR modulators and chemotherapy agents.  
3.4.1 CsA + MECA 
Due to the consistent decrease in cell viability observed following treatment with the cell 
death inhibitors in combination with PnTX in MDA-MB-231 cells, MECA (due to the limited 
availability of PnTX) and CsA were further investigated across a range of toxic and non-toxic 
concentrations to determine the combination relationship between the two compounds.  
The effect of MECA 100 µM and 500 µM combination treatment with CsA 0.1 µM, 1.0 µM 
and 5.0 µM on MDA-MB-231 cell viability was studied following 72 hours of exposure to the 
treatment (Figure 22). No significant combinational effect was seen in cells treated with CsA 0.1 
µM (Figure 22A). However, significant decreases in cell viability were seen following treatment 
with CsA 1.0 µM and CsA 5.0 µM. CsA 1.0 µM + MECA 500 µM combination treatment produced 
a significant decrease in cell viability (P < 0.001), compared to the single treatment with MECA 
500 µM or CsA 1.0 µM (Figure 22B) alone. A similar effect was not seen with CsA 1.0 µM + 
MECA 100 µM; while a strong combinational effect was seen with CsA 5.0 µM treatment (Figure 
22C). CsA 5.0 µM + MECA 100 µM and CsA 5.0 µM + MECA 500 µM produced significant 
decreases in cell viability, compared to the individual treatments (P < 0.001). The CsA 5.0 µM + 
MECA 500 µM treatment demonstrated the greatest combinational effect, resulting in a 91.2% 
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decrease in cell viability, compared to a 23.2% and 8.7% decrease for the respective CsA 5.0 µM 











































































































































































































































































































Figure 22: The cytotoxic effect of combined MECA and CsA treatment in MDA-MB-231 cells. MDA-MB-231 cells were 
treated with MECA 100 µM or 500 µM and CsA 0.1 μM (A), 1.0 µM (B) or 5.0 µM (C), or a combination of the two for 
72 hours following a 24 hour seeding period. Untreated cells were used as a negative control. Cell viability was then 
established via the MTT assay. Values are displayed as the mean percent of the control viability, with error bars 
representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was used to determine significance 




Given the substantial decrease in MDA-MB-231 viability following the combination 
treatment with MECA and CsA, an isobologram was constructed to establish the relationship 
between the two compounds. First, the IC50 values for each individual MECA and CsA treatment 
were calculated and plotted on a dotplot. The line of additivity was then added, connecting the two 
IC50 values. The line of additivity represents the theoretical effect of the two treatments, given each 
treatment acts independently of the other. Next, the IC50 value for each treatment was calculated in 
the presence of a known and constant concentration of the other treatment (e.g. IC50 of MECA in the 
presence of CsA 5.0 μM). The various IC50 values are then plotted on the isobologram to determine 
the relationship between the two treatments. In the event that the interaction between the two 
treatments is more effective than the sum of the single effects (the line of additivity), then it can be 
concluded that the treatments act synergistically. Alternatively, should the effect of the two 
treatments be less effective than the sum of the individual effects, than an antagonistic relationship 
is concluded. A sample diagram highlighting the line of additivity and the two possible 




Figure 23: Isobologram example displaying the line of additivity, connecting the IC50 values for two individual 
treatments. The line of additivity represents the theoretical effect of the two treatments, given each treatment acts 
independently of the other. The line of synergy represents an interaction between two treatments that is more effective 
than the sum of the individual effects. Conversely, the line of antagonism characterises an interaction between the two 
treatments that is less effective than the sum of the individual effects for each treatment. 
 
An isobologram demonstrating the relationship between MECA and CsA treatment of MDA-
MB-231 cells, with respect to cell death, is displayed in Figure 24. The IC50 values for the single 
treatment of MECA and CsA were determined to be 673.6 μM and 28.90 μM respectively. In 
addition, the IC50 values for MECA and CsA were determined when in the presence of a constant 
concentration of the alternate treatment. The IC50 value for CsA decreased to 11.40 μM in the 
presence of MECA 100 μM, and further decreased to 0.9482 μM in the presence of MECA 500 μM. 
Similar reductions in the IC50 value for MECA were seen in the presence of CsA. The IC50 value 
dropped to 364.2 μM for MECA in the presence of CsA 1.0 μM, while further decreasing to 149.0 
μM when in the presence of CsA 5.0 μM. The decrease in IC50 values for MECA and CsA have 
been displayed visually in Figure 24. The data points for the fixed ratio treatment combinations fall 
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well below the line of additivity, representing a pattern of synergistic effect, similar to that shown in 
the example diagram in Figure 23. 
 
Figure 24: Isobologram demonstrating the relationship between MECA and CsA treatment of MDA-MB-231 cells. Cells 
were treated with a range of MECA (10 μM – 1500 μM) and CsA (0.1 μM – 40 μM) for 72 hours, following a 24 hour 
seeding period, to determine the IC50 for each treatment. The line of additivity has been added between the MECA IC50 
value (673.6 μM) and CsA IC50 value (28.90 μM). IC50 values for MECA and CsA, in the presence of constant 
concentrations of the other treatment, are shown to determine the relationship between the two compounds, with 
respect to cell death. 
 
The Annexin V/PI double staining was assessed by flow cytometry to distinguish between 
early apoptotic and necrotic cell death following the individual and combination treatment of MDA-
MB-231 cells. Cells were either left untreated, or treated with CsA 5 μM, MECA 500 μM, or the 
combination of the two. The dotplots showing viable, apoptotic and necrotic cells are presented in 
Figure 25, with the shift in Annexin V staining presented histographically. The results demonstrate 
an increase in Annexin+/PI- apoptotic cells following the various treatments. Small levels of 
apoptotic and necrotic cells were seen in the untreated control cells. A significant increase in early 
apoptotic Annexin+/PI- cells was seen in all treatment groups (P < 0.001). CsA and MECA 
treatment caused moderate increases in Annexin+/PI- cells, with MECA producing a greater 
increase in apoptotic cells (10.50% and 20.34%, respectively). However, combination of the two 
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treatments caused a shift in early apoptotic cells that was significantly higher than either individual 
treatment (44.44%; P < 0.001). Furthermore, the cytotoxic effects of the combination treatment 
caused a dramatic reduction in viable Annexin-/PI- cells to 19.44%, compared to the individual 
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Figure 25: Flow cytometric detection of apoptotic and necrotic cells by fluorescence-activated cell sorting of propidium 
iodide and Annexin V labelled MDA-MB-231 cells. Cells were treated with CsA 5.0 μM (B), MECA 500 μM (C) or CsA 
5.0 μM + MECA 500 μM (D) for 72 hours prior to staining and analysis. Untreated cells (A) were used as a negative 
control. Dot-plots represent viable and apoptotic/necrotic cells. The bottom-left quadrant represents viable cells 
(Annexin-/PI-). The bottom-right quadrant represents early apoptotic cells (Annexin+/PI-). Late apoptotic or secondary 
necrotic cells are represented by the top-right quadrant (Annexin+/PI+). Early apoptotic (Annexin+/PI-) cells were 
graphed (E) with the error bars representing the mean ± SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc 



















3.4.2 Chemotherapy Agents + nAChR Antagonists 
To further investigate the combinational effect of nAChR antagonists with common 
chemotherapy agents in susceptible cell lines, the methods of (Hallett et al., 2012) were adopted. 
A549 and SKBR3 cells were first treated with doxorubicin (DOXO) and docetaxel (DTX), and in 
combination with ADI, to observe the corresponding reduction in cell viability. DOXO 1.0 μM, 
DTX 100 μM and the combination of the two chemotherapy agents in A549 cells caused a moderate 
reduction in cell viability, ranging from ~25-40% reduction in viable cells (Figure 26). Combination 
of the treatments with a relatively weak cytotoxic concentration of ADI 200 μM caused little 
change in the viability of the cell lines, with only DOXO + ADI causing a significant reduction 
from the chemotherapy treatment alone (Figure 26A; P < 0.05). 
Similar results were observed following individual and combination treatment with SKBR3 
cells (Figure 27). A similar decrease in cell viability was seen following DOXO, DTX and DOXO 
+ DTX treatment, resulting in a ~25-60% reduction in viable cells. No significant decrease in cell 
viability was shown when combined with ADI 200 μM, compared to chemotherapy treatment 
alone, for all combinations tested, despite the consistent ~20% reduction in cell viability caused by 























































































































































































































Figure 26: The cytotoxic effect of DOXO, DTX and ADI treatment in A549 cells. A549 cells were treated with DOXO 
1.0 μM (A), DTX 100 μM (B) and DOXO + DTX (C), alone and in combination with ADI 200 μM for 48 hours 
following a 4 hour seeding period. Untreated cells were used as a negative control, while a DMSO vehicle control was 
used for DTX treatment. Cell viability was established via the MTT assay. Values are displayed as the mean percent of 
the control viability, with error bars representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was 






















































































































































































































Figure 27: The cytotoxic effect of DOXO, DTX and ADI treatment in SKBR3 cells. SKBR3 cells were treated with 
DOXO 1.0 μM (A), DTX 100 μM (B) and DOXO + DTX (C), alone and in combination with ADI 200 μM for 48 hours 
following a 4 hour seeding period. Untreated cells were used as a negative control, while a DMSO vehicle control was 
used for DTX treatment. Cell viability was established via the MTT assay. Values are displayed as the mean percent of 
the control viability, with error bars representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc test was 
used to determine significance between treatment groups. 
 
Further analysis of the combinational effects of various nAChR antagonists with the 
combined cytotoxic treatment revealed similar results to those seen for ADI treatment. Relatively 
mild cytotoxic concentrations of nAChR antagonists, including MECA 500 μM, PnTX 1 μM and 
MLA 100 μM, were investigated in combination with DOXO 0.1 μM + DTX 100 μM treatment. No 
significant decrease in cell viability was observed for A549 (Figure 28A) or SKBR3 (Figure 28B) 
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Figure 28: Determination of cell viability following treatment with DOXO, DTX and various nAChR antagonists in 
A549 (A) and SKBR3 (B) cell lines. Cells were treated with DOXO 0.1 μM + DTX 100 μM, MECA 500 μM, PnTX 1μM, 
MLA 100 μM or in various combinations for 48 hours, following a 4 hour seeding period. Untreated cells were used as 
a negative control. Cell viability was established via the MTT assay. Values are displayed as the mean percent of the 
control viability, with error bars representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-hoc was used to 




Finally, the combination of DOXO 0.1 μM with nAChR antagonists was evaluated to 
investigate any significant synergistic effects during cytotoxic combination treatment of cancer 
cells. The viability of MDA-MB-231, HT29 and PC3 cells was measured following treatment with 
DOXO 0.1 μM in combination with ADI 250 μM, MECA 100 μM, MLA 100 μM and 5-HT 100 
μM. A significant decrease in cell viability was observed following DOXO + ADI treatment in 
MDA-MB-231 cells, compared to DOXO treatment alone (P < 0.01; Figure 29A). A similar 
significant decrease in DOXO + ADI and DOXO + MECA was seen in HT29 cells, compared to 
DOXO treatment alone (P < 0.001; Figure 29B). However, no significant decrease in cell viability 
was observed for all other treatment combinations in MDA-MB-231 and HT29 cells, and for all 

















































































































































































































































































































































Figure 29: Evaluation of cell viability following treatment with DOXO and various nAChR antagonists in MDA-MB-
231 (A), HT29 (B) and PC3 (C) cell lines. Cells were treated with DOXO 0.1 μM, ADI 250μM, MECA 500 μM, MLA 
100 μM, 5-HT 100 μM or in various combinations for 48 hours, following a 4 hour seeding period. Untreated cells 
were used as a negative control. Cell viability was established via the MTT assay. Values are displayed as the mean 
percent of the control viability, with error bars representing SEM (n = 3). A one-way ANOVA with a Bonferroni post-




The final studies investigated the possible synergistic effects of the most cytotoxic nAChR 
modulators in combination with various chemotherapy agents. It was hypothesised that the 
combination of nAChR antagonists would enhance the cytotoxic nature of the chemotherapy agents, 
at concentrations that were relatively non-cytotoxic when administered alone. MECA co-treatment 
with CsA was first investigated due to the synergistic effects observed during the apoptotic 
inhibition studies with PnTX and CsA in various carcinoma cell lines (see Section 3.3.1 Cell Death 
Inhibitors). MECA was chosen for continuation of the combination studies due to the unavailability 
of PnTX. Treatment with a combination of MECA and CsA produced significant increases in 
carcinoma cell death, compared to the individual treatments. The relationship between the two 
compounds was determined as synergistic, with a significant reduction in IC50 value for CsA when 
in the presence of relatively non-cytotoxic concentrations of MECA. From the isobologram, it 
seems CsA has the greater effect on the IC50 of MECA. 
The isobologram results demonstrated a synergistic effect between MECA and CsA. The 
swayed nature of the IC50 points suggests that the synergistic effects are more evident under 
different combinations of the two compounds. The presence of CsA has a greater effect on the IC50 
of MECA, potentiating the cytotoxic effects of MECA presumably through enhancing the 
downstream effects of nAChR antagonism. CsA acts via inhibiting the cyclophilin D protein, 
preventing the opening of the mitochondrial permeability transition pore during apoptosis. 
However, the results from studies with both MECA and PnTX suggest a secondary action of CsA, 
whereby CsA acts as a phosphatase 2B inhibitor, with the ability to affect the desensitisation status 
of nAChRs. Marszalec and colleagues previously investigated the desensitisation of nAChR during 
modulation of kinase activation and phosphatase inhibition (Marszalec et al., 2005). The study 
showed that nAChRs are present as two interconverting states of desensitisation, a rapidly 
recovering D1 state, and a slower recovering D2 state. nAChRs important in cancer development, 
such as the α4β2 subtype, are often driven towards the slowly recovering D2 state following 
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continuous exposure to receptor modulators. The blocking action of CsA reduces the overall 
desensitisation of nAChRs by facilitating a shift toward the faster recovering D1 receptor state 
through the inhibition of nAChR dephosphorylation (Marszalec et al., 2005).  The phosphatase 2B 
inhibitory effects in the present combination study would effectively enhance the activity of the 
potent nAChR antagonists, MECA and PnTX, resulting in the observed synergistic cytotoxic 
effects. Consequently, CsA could potentially be used as a sensitising agent to enhance the effects of 
nAChRs antagonists in cancer cell death.  
Studies involving the co-treatment of carcinoma cell lines with nAChR modulators and 
chemotherapy agents, doxorubicin and docetaxel, were conducted to further explore the possible 
synergistic effects of the combination treatments. The present studies were based on those 
previously performed by Hallet et al, where co-treatment of ADI with the chosen chemotherapy 
agents produced a significant synergistic effect in a range of ‘sensitive’ carcinoma cell lines. The 
study showed a significant synergistic effect was observed at concentrations of the two treatments 
that would not elicit a cytotoxic response when administered individually. The present study used a 
range of carcinoma cell lines, including the A549 and SKBR3 cell lines used in the Hallet et al 
study, with similar concentrations of the treatments in an attempt to replicate and further the studies 
previously reported. Contrasting results were observed during the present study, with co-treatment 
of ADI and other nAChR modulators with the chemotherapy agents producing no clear synergistic 
cytotoxic effects. Differences in the method used to determine cell viability between the present 
studies (MTT assay), and the literature (AlamarBlue reduction method) may have contributed to the 
conflicting results. The AlamarBlue viability assay is based on the reduction of the non-fluorescent 
reagent resazurin, to the fluorescent compound resarufin, by viable cells. However, studies have 
shown the reagent can interact and convert to the fluorescent compound through interactions with 
various cell media types, independent of the presence of living cells. Incubation periods up to 4 
hours produced ~15% increase in relative fluorescence when incubated in cell media without the 
presence of cells (Munshi et al., 2014). This effect may have exacerbated the difference in treatment 
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groups in the results by Hallet et al during the 24 hour incubation of AlamarBlue to determine cell 
viability; while little differences were observed in the present study. 
 The concept of combining selective nAChR antagonists with chemotherapeutic agents is one 
that has been alluded to throughout the current literature. Studies, such as that conducted with the 
selective α7 antagonist, APS8, have demonstrated an ability to sensitise cells to apoptosis. NIC 
treatment of SKMES-1 cells has been shown to increase the expression of a family of pro-survival 
proteins, the inhibitors of apoptosis proteins (IAPs). The endogenous proteins bind and inactivate 
caspases, effectively inhibiting cancer cell apoptosis. APS8 treatment was shown to be an effective 
antagonist IAP activity. The results suggest that APS8 treatment was capable of preventing NIC-
induced resistance to apoptosis, by interfering with IAP activity, allowing the downstream 
activation of caspases and ultimately cell apoptosis to occur (Zovko et al., 2013). Theoretically, 
such effects of α7-nAChR antagonism would sensitise cancer cells to conventional chemotherapy 
agents that attempt to induce apoptotic pathways. Doxorubicin and docetaxel both act via cytotoxic 
mechanisms that do not directly target cancer cell apoptotic pathways. The present studies showed 
no significant sensitisation to both chemotherapeutic agents when combined with various nAChR 
antagonists. Combination of such antagonists with chemotherapeutic compounds that target specific 





4.1 Signalling through nAChRs is linked to Cancer Development 
4.1.1 nAChR Agonist Induced Cancer Progression 
In 2009, Schuller published a pivotal review highlighting the potential causal link between 
smoking and nAChR driven tumour growth and metastasis. Nicotine and the highly potent nicotine-
derived nitrosamines are now recognised as potent agonists of nAChRs  (Schuller, 2009). These 
agonists promote carcinogenesis by stimulating angiogenesis and inhibiting apoptosis through 
binding to the α7 subunit of the nAChR (Jull et al., 2001). Blocking these effects through the use of 
selective antagonists offers new opportunities for the development of mechanisms that reduce 
cancer development and progression.  
4.1.2 nAChR Antagonist Driven Cytotoxicity 
The recently identified family of shellfish toxins, PnTXs, demonstrate high antagonistic 
affinity towards α7-nAChRs (Hellyer et al., 2011). In this research, PnTX-driven nAChR 
antagonism demonstrated the most profound effect on cancer cell viability of all the antagonists 
tested. The cytotoxic effects were more distinguishable in the adenocarcinoma cells lines, 
highlighting expression of nAChRs outside of the nervous system. 
Flow cytometry studies showed that treatment of the MDA-MB-231, HT29 and PC3 
carcinoma cell lines with the nAChR antagonists MECA, ADI and 5-HT (through secondary 
antagonistic effects) induces DNA fragmentation and opening of the mitochondrial transition pore, 
indicative of early apoptosis. Interestingly, flow cytometry and apoptotic inhibition studies 
suggested an alternative mechanism for PnTX induced cytotoxicity compared to the other nAChR 
antagonists investigated. PnTX treatment induced a small, but significant increase in apoptotic cells 
within the sub-G1 fraction of the cell cycle; while only displaying a slight increase in the 
mitochondrial membrane permeability of treated cells. The flow cytometry profile of PnTX was 
significantly different to that of the MECA, ADI and 5-HT treatment, despite displaying 
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comparable cytotoxic effects during viability studies. Although a proposed mechanism for PnTX-
induced cell death of carcinoma cells has not been previously documented in the literature, the 
present study suggests a cytotoxic mechanism associated with the ability of the α7-nAChR to 
regulate intracellular calcium levels. 
 
4.2 The nAChR Antagonist PnTX Induces Cytotoxicity by Altering 
Intracellular Calcium Levels 
The present study suggests that the cytotoxic effects of PnTX are mediated through the 
observed antagonism of the highly permeable α7-, and to a lesser extent the α4β2-nAChRs, 
inducing cell apoptosis through calcium-independent pathways. 
Cell cycle analysis showed a potential G0/G1 phase arrest following PnTX treatment. 
Transient rises in [Ca2+] are integral to the process of cell division (Kahl et al., 2003), suggesting 
that changes in [Ca2+] through antagonism of α7 and α4β2 may play a role during PnTX treatment. 
To investigate the mechanism of PnTX cytotoxicity further, inhibitors of common apoptotic 
pathways were used in an attempt to reduce the cytotoxic effects of PnTX. PnTX-induced cell 
cytotoxicity was not affected by the inhibition of the various intrinsic apoptotic processes, 
suggesting an alternative mechanism for PnTXs cytotoxic effects. Intracellular calcium studies 
revealed that following PnTX treatment there is a prolonged decrease in [Ca2+], suggesting a 
possible cytotoxic action by inducing cell apoptosis through Ca2+-independent pathways. Although 
the limited supply of PnTX available at the time of this research meant the experiments could not be 




4.3 Synergistic Cytotoxic Effects of Selective nAChR Antagonists with 
Common Chemotherapeutic Agents 
A second promising outcome of this research was the demonstration that selective nAChR 
antagonists enhance the cytotoxicity of common chemotherapeutic agents. The effect of nAChR 
antagonist treatment was assessed in combination with CsA and common chemotherapeutic agents 
to explore the synergistic capacity of the compounds. The combination of nAChR antagonists was 
expected to enhance the cytotoxic nature of the chemotherapeutic agents through sensitisation of the 
cancer cells (Hallett et al., 2012). Contrary to expectations, combination of the nAChR antagonists 
with doxorubicin and docetaxel displayed no synergistic effects, inconsistent with previous 
literature. Alternatively, MECA treatment in combination with CsA produced a significant increase 
in carcinoma cell death and early apoptotic cells, compared to the individual treatments. The 
relationship between the two compounds was determined as synergistic based on the isobologram 
results. The synergistic cytotoxic effects are attributed to the secondary action of CsA through 
phosphatase 2B inhibition, effectively enhancing the activity of the potent nAChR antagonists. CsA 
could potentially be used as a sensitising agent to enhance the effects of nAChRs antagonists in 
cancer cell death. Although similar results were demonstrated when CsA was further investigated 
with MECA, PnTX would have been the preferred investigational treatment. 
 
4.4 Future Directions 
The present study has established the relative cytotoxic nature of several nAChR modulators. 
To further investigate the importance of nAChR in cancer development and whether nAChR 
overexpression of nAChR can be used to selectively exploit cancer cells, studies on healthy 
epithelial cells should be conducted. Previous studies, such as that conducted by Zovko and 
colleagues on the apoptotic effects of APS8, have suggested that the antagonistic effects of selective 
α7-nAChRs do not affect the proliferation of normal healthy cells. A possible theory for why 
selective α7-nAChR antagonists, such as PnTX, may have a differential effect between normal and 
110 
 
cancer cells, could be due to the number of binding sites present on the different cell types. Current 
literature has repeatedly demonstrated the upregulation of the α7-nAChR in various cancer cell 
types; while the present study has hinted at a significant relationship between greater levels of α7-
nAChR expression and an increased response to nAChR modulators. Studies looking at the effect of 
PnTX on the viability and apoptotic induction of healthy epithelial cells would assist in determining 
the possibility of exploiting nAChR overexpression in cancer treatment.  
 Further investigation into the cytotoxic mechanism of PnTX on the various carcinoma cell 
types would play an important role in deducing the effects of nAChR in cancer cell death. 
Observations from the present study have determined that decreases in intracellular calcium 
following PnTX treatment are the likely cause of the cytotoxic effects. Knockout studies of various 
nAChR subtypes, including the highly permeable α7 subunit, would further consolidate the present 
findings. However, the complete mechanism and second messengers involved downstream of the 
changes in intracellular calcium have not been determined. As discussed previously, Ca2+ is 
important for the expression of the cell cycle genes, FOS, JUN and MYC. Investigation into the 
changes in FOS, JUN and MYC expression during PnTX treatment would assist in determining 
whether the decrease in intracellular calcium is having a significant effect on the cancer cell cycle. 
Additionally, studies using PnTX to replicate the combination effect seen between MECA and CsA 
treatment should be conducted, to investigate whether similar synergistic effects are observed. 
Combination treatment of PnTX and CsA conducted on nAChR knockout cells would supplement 
the current theory that CsA has a significant effect on the sensitivity of nAChRs to PnTX treatment. 
Although the findings of this research highlight the potential application of nAChR 
modulators in controlling cancer cell proliferation, further development is essential before they 
could be used in a clinical setting. Naturally occurring antagonists often display potent inhibitory 
actions on neuromuscular nAChRs, making them highly toxic when administered in vivo (Zovko et 
al., 2013). The antagonistic behaviour at the neuromuscular junction often occurs at concentrations 
below those required to induce cytotoxic effects on cancer cells, limiting the potential clinical use of 
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such nAChR antagonists. PnTX falls into this category with potent effects on neuromuscular 
nAChRs at a concentration of ~500 nM (Hellyer et al., 2011). The potential clinical use of nAChR 
antagonists in cancer treatment would require alteration to the chemical structures that limit their 
effects at the neuromuscular junction, while sustaining the potent effect on non-neuronal nAChRs. 
Alternatively, a better understanding of how nAChR antagonists induce cancer cell cytotoxicity 
may allow targeting of downstream effector molecules that eliminate the need for selective 
targeting of nAChRs.  
 
4.5 Final Conclusion 
This research has identified a novel mechanism for the observed cytotoxicity of the highly 
potent nAChR antagonist, PnTX, on human epithelial carcinoma cell lines. Cell cycle and 
intracellular calcium studies suggest that PnTX exerts its cytotoxic effects by inducing changes in 
the cell cycle via antagonism of the highly calcium permeable α7-, and to a certain extent, the α4β2-
nAChR receptors. This leads to an induction of cell apoptosis via calcium-independent pathways. 
The use of nAChRs in combination with other known cytotoxic agents, such as CsA or apoptotic 
inducing chemotherapy agents, may provide a sensitising tool that can reduce the dose required to 
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